Blood and Marrow Transplant Clinical Trials Network

Re-Admission/Hospitalization Form (ADM)

Web Version: 1.0; 4.07; 10-16-15

Segment *(PROTSEG)*:
Date of Admission *(ADMITDT)*:

1. Date of discharge:*(DISCHDT)* _____ *(mm/dd/yyyy)*
2. Patient discharge status:*(DISCPTST)* ☐ 1 - Alive ☐ 2 - Dead
   If Dead, a Death Form must be submitted.
3. Record PRIMARY discharge diagnosis:*(PHSPREAS)*

```
01 - GVHD
02 - Relapse/Progression
03 - Graft Failure
04 - Infection
05 - Fungal Infection
*Additional Options Listed Below
```

   Specify organ:(ADM4SPEC)* _____
   **Specify other:*(ADM1SPEC)* _____
4. Record secondary discharge diagnoses:

a. GVHD:*(REASGVHD)*	☐ 1 - Contributory	☐ 2 - Noncontributory
b. Relapse/progression:*(REASRLPS)*	☐ 1 - Contributory	☐ 2 - Noncontributory
c. Graft failure:*(REASGF)*	☐ 1 - Contributory	☐ 2 - Noncontributory
d. Infection:*(REASINF)*	☐ 1 - Contributory	☐ 2 - Noncontributory
e. Fever:*(REASFVR)*	☐ 1 - Contributory	☐ 2 - Noncontributory
f. Seizure:*(REASSZR)*	☐ 1 - Contributory	☐ 2 - Noncontributory
g. Bleeding/hemorrhage:*(REASGIBL)*	☐ 1 - Contributory	☐ 2 - Noncontributory
h. Diarrhea:*(REASDRH)*	☐ 1 - Contributory	☐ 2 - Noncontributory
i. Nausea/vomiting:*(REASNV)*	☐ 1 - Contributory	☐ 2 - Noncontributory
j. Organ failure:*(REASORGF)*	☐ 1 - Contributory	☐ 2 - Noncontributory
Specify organ:*(ADM3SPEC)*		
k. Trauma:*(REASTRAM)*	☐ 1 - Contributory	☐ 2 - Noncontributory
l. Psychiatric:*(REASPSYC)*	☐ 1 - Contributory	☐ 2 - Noncontributory
m. Secondary malignancy:*(REASMALG)*	☐ 1 - Contributory	☐ 2 - Noncontributory
n. Scheduled procedure/treatment:*(REASPROC)*	☐ 1 - Contributory	☐ 2 - Noncontributory
o. Thrombosis/thrombus/embolism:*(REASTRMB)*	☐ 1 - Contributory	☐ 2 - Noncontributory
p. Other:*(REASOTHR)*	☐ 1 - Contributory	☐ 2 - Noncontributory
Specify other:*(ADM2SPEC)*		

5. Record re-admission institution:*(ADMCENTR)*

```
1 - Original Transplant Center
2 - Other Transplant Center
3 - Other Hospital
```

Comments:*(ADMCOMM1)*

Additional Selection Options for ADM

Record PRIMARY discharge diagnosis:
06 - Non-Fungal Infection
07 - Fever
08 - Seizure
09 - Bleeding/Hemorrhage
10 - Diarrhea
11 - Nausea/Vomiting
12 - Organ Failure (specify organ)*
13 - Trauma
14 - Psychiatric
15 - Secondary Malignancy
16 - Transplant
17 - Scheduled Procedure/Treatment
18 - Thrombosis/Thrombus/Embolism
99 - Other (specify)**

Blood and Marrow Transplant Clinical Trials Network

Adverse Event Form (AE1)

Web Version: 1.0; 4.00; 10-16-15

Segment *(PROTSEG)*:
Date of Onset *(ADVDATE)*:
Event description *(ADVENT)*:

1. Report activation status:*(AVSTATUS)*
   - 1 - Keep report active
   - 2 - Deactivate - Report filed in error
   - 3 - Deactivate - Key field error
   - 9 - Deactivate - Other reason

   If Other, specify reason for deactivation:*(AESPEC1)*
2. Record date transplant center became aware of the event:*(AVAWARDT)* *(mm/dd/yyyy)*
3. Indicate weight at time of the event:*(AVWGHTKG)* *(xxx.x)* kg
4. Was this event expected or anticipated?*(AVEXPECT)* ☐ 1 - Yes ☐ 2 - No
5. Record the severity of event:*(AVEVENT)*
   - 1 - Mild
   - 2 - Moderate
   - 3 - Severe
   - 4 - Life Threatening
   - 5 - Fatal
6. What is the relationship to study therapy/intervention:*(AVRELAT)*
   - 1 - Unrelated
   - 2 - Unlikely
   - 3 - Possible
   - 4 - Probable
   - 5 - Definite
7. Is there an alternative etiology:*(AVETIOL)*
   - 0 - None Apparent
   - 1 - Study Disease
   - 2 - Other Pre-Existing Disease or Condition
   - 3 - Accident, Trauma, or External Factors
   - 4 - Concurrent Illness/Condition (Not Pre-Existing)
8. What is the effect on study therapy/intervention schedule:*(AVEFFECT)*
   - 1 - No Change - Completed
   - 2 - No Change - Ongoing
   - 3 - Dose Modified
   - 4 - Temporarily Stopped
   - 5 - Permanently Stopped
9. Record the most severe outcome of the event:*(AVOUTCOM)*
   - 1 - Resolved, No Residual Effects
   - 2 - Resolved with Sequelae
   - 3 - Persistent Condition
   - 4 - Resolved by Death
10. Record the date of resolution:*(AVRESDT)* *(mm/dd/yyyy)*
11. Was this event associated with:*(AVASSOCI)*
    - 0 - None of the Following
    - 1 - Death
    - 2 - Life-Threatening Event
    - 3 - Disability
    - 4 - Congenital Anomaly
    - *Additional Options Listed Below

Comments:*(AE1COMM)*

Additional Selection Options for AE1

Was this event associated with:
5 - Required Intervention to Prevent Permanent Impairment or Damage
6 - Hospitalization (Initial or Prolonged)
9 - Other SAE

Blood and Marrow Transplant Clinical Trials Network

AE Summary Form (AE2)

Web Version: 1.0; 3.12; 10-16-15

Segment *(PROTSEG)*:
Date of Onset *(ADVDATE)*:
Event description *(ADVENT)*:

1. Report activation status:*(AVSTAT_A)*

1 - Keep report active
2 - Deactivate - Report filed in error
3 - Deactivate - Key field error
9 - Deactivate - Other reason

Relevant Past Medical History

2. Does the patient have any relevant history, including pre-existing medical conditions?*(SEMEDHXS)* ☐ 1 - Yes ☐ 2 - No

If Yes, include any relevant history, including preexisting medical conditions below.

(SEMEDHX)

3. **Event Summary**

Include clinical history of event, associated signs and symptoms, alternative etiologies being considered and medical management below.

(SESUMM)

4. Initial submitter:*(SEISUBBY)* Name: Date:*(SEISUBDT)* *(mm/dd/yyyy)*

5. Authorized submitter:*(SEASUBBY)* Name: Date:*(SEASUBDT)* *(mm/dd/yyyy)* ?

Blood and Marrow Transplant Clinical Trials Network

AE Therapy Form (AE3)

Web Version: 1.0; 4.05; 10-16-15

Segment *(PROTSEG)*:
Date of Onset *(ADVDATE)*:
Event description *(ADVENT)*:

1. Report activation status:*(AVSTAT_B)*

1 - Keep report active
2 - Deactivate - Report filed in error
3 - Deactivate - Key field error
9 - Deactivate - Other reason

Study Product/Suspect Medication Data

2. Was the patient receiving any study products/suspect medications?*(RCVSP)* ☐ 1 - Yes ☐ 2 - No

If Yes, list the study product/suspect medications the subject was taking in the grid below.

Study Product Name (Note: If blinded, indicate as such)	Dose of Study Product(s) at SAE Onset	Route of Study Product(s) at SAE Onset	Schedule of Study Product(s) at SAE Onset	Date Study Product First Started *(mm/dd/yyyy)*	Date Study Product Last Taken *(mm/dd/yyyy)*	Reason for Use
(SPNAME1)	*(SP1DOSE)*	*(SP1ROUTE)*	*(SP1SCHED)*	*(SP1STDT)*	*(SP1SPDT)*	*(SP1REASO)*
(SPNAME2)	*(SP2DOSE)*	*(SP2ROUTE)*	*(SP2SCHED)*	*(SP2STDT)*	*(SP2SPDT)*	*(SP2REASO)*
(SPNAME3)	*(SP3DOSE)*	*(SP3ROUTE)*	*(SP3SCHED)*	*(SP3STDT)*	*(SP3SPDT)*	*(SP3REASO)*
(SPNAME4)	*(SP4DOSE)*	*(SP4ROUTE)*	*(SP4SCHED)*	*(SP4STDT)*	*(SP4SPDT)*	*(SP4REASO)*
(SPNAME5)	*(SP5DOSE)*	*(SP5ROUTE)*	*(SP5SCHED)*	*(SP5STDT)*	*(SP5SPDT)*	*(SP5REASO)*

Concomitant Medications

3. Was the patient taking any concomitant medications?*(RCVCONMD)* ☐ 1 - Yes ☐ 2 - No

If Yes, list the concomitant medications the patient was taking up to 1 month prior to SAE onset in the grid below.

Medication	Start Date *(mm/dd/yyyy)*	Stop Date *(mm/dd/yyyy)*	Dose, Route, Schedule	Indication
(CONMED1)	*(CM1STDT)*	*(CM1SPDT)*	*(CM1DOSE)*	*(CM1INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED2)	*(CM2STDT)*	*(CM2SPDT)*	*(CM2DOSE)*	*(CM2INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED3)	*(CM3STDT)*	*(CM3SPDT)*	*(CM3DOSE)*	*(CM3INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED4)	*(CM4STDT)*	*(CM4SPDT)*	*(CM4DOSE)*	*(CM4INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED5)	*(CM5STDT)*	*(CM5SPDT)*	*(CM5DOSE)*	*(CM5INDIC)*

				1 - Treatment of adverse event 9 - Other
(CONMED6)	*(CM6STDT)*	*(CM6SPDT)*	*(CM6DOSE)*	*(CM6INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED7)	*(CM7STDT)*	*(CM7SPDT)*	*(CM7DOSE)*	*(CM7INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED8)	*(CM8STDT)*	*(CM8SPDT)*	*(CM8DOSE)*	*(CM8INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED9)	*(CM9STDT)*	*(CM9SPDT)*	*(CM9DOSE)*	*(CM9INDIC)* 1 - Treatment of adverse event 9 - Other
(CONMED10)	*(CM10STDT)*	*(CM10SPDT)*	*(CM10DOSE)*	*(CM10INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED11)	*(CM11STDT)*	*(CM11SPDT)*	*(CM11DOSE)*	*(CM11INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED12)	*(CM12STDT)*	*(CM12SPDT)*	*(CM12DOSE)*	*(CM12INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED13)	*(CM13STDT)*	*(CM13SPDT)*	*(CM13DOSE)*	*(CM13INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED14)	*(CM14STDT)*	*(CM14SPDT)*	*(CM14DOSE)*	*(CM14INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED15)	*(CM15STDT)*	*(CM15SPDT)*	*(CM15DOSE)*	*(CM15INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED16)	*(CM16STDT)*	*(CM16SPDT)*	*(CM16DOSE)*	*(CM16INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED17)	*(CM17STDT)*	*(CM17SPDT)*	*(CM17DOSE)*	*(CM17INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED18)	*(CM18STDT)*	*(CM18SPDT)*	*(CM18DOSE)*	*(CM18INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED19)	*(CM19STDT)*	*(CM19SPDT)*	*(CM19DOSE)*	*(CM19INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED20)	*(CM20STDT)*	*(CM20SPDT)*	*(CM20DOSE)*	*(CM20INDI)* 1 - Treatment of adverse event 9 - Other

(CONMED21)	*(CM21STDT)*	*(CM21SPDT)*	*(CM21DOSE)*	*(CM21INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED22)	*(CM22STDT)*	*(CM22SPDT)*	*(CM22DOSE)*	*(CM22INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED23)	*(CM23STDT)*	*(CM23SPDT)*	*(CM23DOSE)*	*(CM23INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED24)	*(CM24STDT)*	*(CM24SPDT)*	*(CM24DOSE)*	*(CM24INDI)* 1 - Treatment of adverse event 9 - Other
(CONMED25)	*(CM25STDT)*	*(CM25SPDT)*	*(CM25DOSE)*	*(CM25INDI)* 1 - Treatment of adverse event 9 - Other

Comments:*(AE3COMM)*

Blood and Marrow Transplant Clinical Trials Network

AE Laboratory/Diagnostics Form (AE4)

Web Version: 1.0; 3.11; 10-16-15

Segment *(PROTSEG)*:
Date of Onset *(ADVDATE)*:
Event description *(ADVENT)*:

1. Report activation status:*(AVSTAT_C)*

1 - Keep report active
2 - Deactivate - Report filed in error
3 - Deactivate - Key field error
9 - Deactivate - Other reason

Laboratory Test Results

2. Were relevant laboratory tests performed?*(LABTSTPF)* ☐ 1 - Yes ☐ 2 - No

If Yes, record the relevant laboratory test results in the gird below.

Test	Collection Date *(mm/dd/yyyy)*	Result (Include units)	Site Normal Range (Include units)	Lab Value Previous to this SAE (Include units)	Collection Date for Previous Lab *(mm/dd/yyyy)*
(ADLTST1)	*(ADL1CD)*	*(ADL1RES)*	*(ADL1NORG)*	*(ADL1PRVL)*	*(ADL1PCD)*
(ADLTST2)	*(ADL2CD)*	*(ADL2RES)*	*(ADL2NORG)*	*(ADL2PRVL)*	*(ADL2PCD)*
(ADLTST3)	*(ADL3CD)*	*(ADL3RES)*	*(ADL3NORG)*	*(ADL3PRVL)*	*(ADL3PCD)*
(ADLTST4)	*(ADL4CD)*	*(ADL4RES)*	*(ADL4NORG)*	*(ADL4PRVL)*	*(ADL4PCD)*
(ADLTST5)	*(ADL5CD)*	*(ADL5RES)*	*(ADL5NORG)*	*(ADL5PRVL)*	*(ADL5PCD)*
(ADLTST6)	*(ADL6CD)*	*(ADL6RES)*	*(ADL6NORG)*	*(ADL6PRVL)*	*(ADL6PCD)*
(ADLTST7)	*(ADL7CD)*	*(ADL7RES)*	*(ADL7NORG)*	*(ADL7PRVL)*	*(ADL7PCD)*
(ADLTST8)	*(ADL8CD)*	*(ADL8RES)*	*(ADL8NORG)*	*(ADL8PRVL)*	*(ADL8PCD)*
(ADLTST9)	*(ADL9CD)*	*(ADL9RES)*	*(ADL9NORG)*	*(ADL9PRVL)*	*(ADL9PCD)*
(ADLTST10)	*(ADL10CD)*	*(ADL10RES)*	*(ADL10NRG)*	*(ADL10PVL)*	*(ADL10PCD)*

Diagnostic Tests (EX: MR, CT Scan, Ultrasound)

3. Were relevant diagnostic tests performed?*(DXSTPF)* ☐ 1 - Yes ☐ 2 - No

If Yes, record the relevant diagnostic test results in the grid below. Submit copies of the diagnostic test if available.

Test	Date Performed *(mm/dd/yyyy)*	Results/Comments

(ADDTS1)	*(AD1DTDAT)*	*(AD1DTRES)*
(ADDTS2)	*(AD2DTDAT)*	*(AD2DTRES)*
(ADDTS3)	*(AD3DTDAT)*	*(AD3DTRES)*
(ADDTS4)	*(AD4DTDAT)*	*(AD4DTRES)*
(ADDTS5)	*(AD5DTDAT)*	*(AD5DTRES)*

(ADDTS6)	*(AD6DTDAT)*	*(AD6DTRES)*
(ADDTS7)	*(AD7DTDAT)*	*(AD7DTRES)*
(ADDTS8)	*(AD8DTDAT)*	*(AD8DTRES)*
(ADDTS9)	*(AD9DTDAT)*	*(AD9DTRES)*
(ADDTS10)	*(AD10DTDT)*	*(AD10DTRS)*

Comments:*(AE4COMM)*



Blood and Marrow Transplant Clinical Trials Network

AE Review Form (AE5)

Web Version: 1.0; 3.12; 10-16-15

Segment *(PROTSEG)*:
Date of Onset *(ADVDATE)*:
Event description *(ADVENT)*:

1. Report activation status:*(AVSTAT_D)*

1 - Keep report active
2 - Deactivate - Report filed in error
3 - Deactivate - Key field error
9 - Deactivate - Other reason

2. Reviewed:*(AEREVIEW)* ☐ 1 - Yes ☐ 2 - No
3. Reviewed by:*(ARFREVBY)*
4. Review date:*(ARFREVDT)* *(mm/dd/yyyy)*

5. Comment 1 - For Distribution:*(ARCM1DIS)*

6. Comment 2 - All Other Reviewers/Data Coordinating Center*(ARCM2ALL)*

Blood and Marrow Transplant Clinical Trials Network

AE Medical Monitor Reviewer Form (AE6)

Web Version: 1.0; 7.00; 10-16-15

Segment *(PROTSEG)*:
Date of Onset *(ADVDATE)*:
Event description *(ADVENT)*:

1. Adverse event status:*(AVSTAT_E)*

1 - Keep report active
2 - Deactivate - Report filed in error
3 - Deactivate - Key field error
9 - Deactivate - Other reason

2. Has this event been determined to be an unexpected, grade 3-5 adverse event? *(AMDETER)* ☐ 1 - Yes ☐ 2 - No
3. Does this require expedited reporting to the DSMB?*(AMEXPDSM)* ☐ 1 - Yes ☐ 2 - No
4. Do you recommend the patient be withdrawn from further protocol therapy? *(AMWITHDR)* ☐ 1 - Yes ☐ 2 - No
5. Is the review complete?*(AMREVDNE)* ☐ 1 - Yes ☐ 2 - No
6. If **No**, what additional information is required:*(AMREVINF)*
7. Medical Monitor event description:*(AMMMEVDS)*
8. Medical Monitor CTCAE grade of event:*(CTCAEGRD)*

1 - Grade 1
2 - Grade 2
3 - Grade 3
4 - Grade 4
5 - Grade 5

Comments:*(AE6COMM)*

Blood and Marrow Transplant Clinical Trials Network

Follow Up GVHD Form (CGV)

Web Version: 1.0; 7.04; 10-16-15

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

1. Start of assessment period:*(DTPRVAST)* *(mm/dd/yyyy)*
2. End of assessment period:*(DTASSESS)* *(mm/dd/yyyy)*

Answer questions 3-9 relating to acute GVHD.

3. Maximum overall grade of acute GVHD during this assessment period:*(GRDAGVHD)*
   - 0 - No Symptoms of Acute GVHD
   - 1 - I
   - 2 - II
   - 3 - III
   - 4 - IV
4. Did clinical signs and/or symptoms of acute GVHD develop during this assessment period?*(AGVDVLP)* 1 - Yes 2 - No ?
5. Record method used to diagnose acute GVHD:*(DGNSAGVH)*
   - 1 - Histologic Evidence
   - 2 - Clinical Evidence
   - 3 - Both
6. Date of diagnosis of acute GVHD:*(DTDGNAGV)* *(mm/dd/yyyy)* ?
7. Was prophylaxis for GVHD given during this assessment period?*(PROPHIMM)*
   - 1 - Yes
   - 2 - No
   - 3 - Discontinued During This Assessment Period
8. If yes, specify all immunosuppressants used for GVHD prophylaxis:
   a. Cyclosporine:*(PROPHCY)* 1 - Yes 2 - No
   b. Tacrolimus:*(PROPHTAC)* 1 - Yes 2 - No
   c. Sirolimus:*(PROPHSIR)* 1 - Yes 2 - No
   d. MMF:*(PROPHMMF)* 1 - Yes 2 - No
   e. Prednisone:*(PROPHPRD)* 1 - Yes 2 - No
   f. Other:*(PROPHOTH)* 1 - Yes 2 - No
   Specify other agent used:*(PRPHOTSP)*
9. If GVHD prophylaxis was discontinued during this assessment, record the date:*(PRPHDISC)* *(mm/dd/yyyy)*

Answer questions 10-20 relating to chronic GVHD.

10. Maximum overall severity of chronic GVHD during this assessment period:*(SEVCGVHD)*
    - 0 - No Symptoms of Chronic GVHD
    - 1 - Mild
    - 2 - Moderate
    - 3 - Severe
11. Maximum overall grade of chronic GVHD during this assessment period:*(GRDCGVHD)* 1 - Limited 2 - Extensive ?
12. Did clinical signs and/or symptoms of chronic GVHD develop during this assessment period?*(CGVDVLP)* 1 - Yes 2 - No ?
13. Record method used to diagnose chronic GVHD:*(DGNSCGVH)*
    - 1 - Histologic Evidence
    - 2 - Clinical Evidence
    - 3 - Both
14. Date of diagnosis of chronic GVHD:*(DTDGNCGV)* *(mm/dd/yyyy)* ?

15. Minimum Karnofsky/Lansky Score at time of diagnosis: *(CGVKRNLN)*

```
01 - 100 (Normal; No Complaints/Fully Active)
02 - 90 (Normal Activity/Minor Restriction in Strenuous Play)
03 - 80 (Normal Activity with Effort/Restricted in Strenuous Play)
04 - 70 (Unable to Carry On Normal Activity/Less Time Spent in Play)
05 - 60 (Requires Occasional Assistance/Minimal Active Play)
*Additional Options Listed Below
```

16. Minimum platelet count at time of diagnosis: *(PLTLTCNT)* *(xxx.x)* x 10^9/L

17. Alkaline phosphatase at time of diagnosis: *(ALKPHOSP)* *(xxxx)* U/L

18. Weight at time of diagnosis: *(CGVWEIGH)* *(xxx.x)* kg

19. Total bilirubin at time of diagnosis: *(BILIRUBN)* *(xx.x)* mg/dL

20. Body surface area involved with rash at time of diagnosis: *(BSA)* *(xxx)* % ?

Indicate the maximum severity of involvement for the following organ systems during this assessment period.

Skin/Hair

21. Extent of skin involvement: *(CGVRASH)*

```
0 - No Rash
1 - <25% of BSA Involvement
2 - 25-50% of BSA Involvement
3 - >50% of BSA Involvement
4 - Generalized Involvement
```

?

If there is skin involvement, indicate the type of rash:

a. Lichenoid: *(RASHLICH)* ☐ 1 - Yes ☐ 2 - No

b. Maculopapular: *(RASHMACU)* ☐ 1 - Yes ☐ 2 - No

c. Sclerodermatous: *(RASHSCLR)* ☐ 1 - Yes ☐ 2 - No

Ocular

22. Xerophthalmia: *(DRYEYES)*

```
0 - No Symptoms
1 - Dry Eyes but Not Requiring Therapy
2 - Dryness of Eyes or Inflammation Requiring Therapy
```

Oral

23. Mucositis/ulcers (functional): *(MUCOFXN)*

```
0 - No Symptoms
1 - Minimal Symptoms, Normal Diet
2 - Symptomatic but Can Eat and Swallow Modified Diet
3 - Symptomatic and Unable to Adequately Alimentor Hydrate Orally
```

Pulmonary

24. Dyspnea: *(CGVDYSPN)*

```
0 - Asymptomatic
1 - Dyspnea with Exertion
2 - Dyspnea with Normal Activities
3 - Dyspnea at Rest
```

25. Pulmonary fibrosis: *(PULMFIBR)*

```
0 - None
1 - Minimal Radiographic Findings
2 - Patchy or Bi-basilar Radiographic Findings
3 - Extensive Radiographic Findings
9 - Not Done
```

26. Bronchiolitis obliterans: *(BRNCOBLT)*

```
1 - Yes, Histologic diagnosis
2 - Yes, Clinical diagnosis
3 - No
4 - Unknown
```

27. FEV1: *(CGVFEV1)*

```
0 - 100-90%
1 - <90-75%
2 - <75-50%
3 - <50-25%
4 - <25%
```

28. Oxygen saturation:*(O2SAT)*

0 - No Symptoms
1 - Desaturation with Exercise
2 - Requires Supplemental Oxygen

Gastrointestinal

29. Esophagus:*(ESOPHAGS)*

0 - No Changes
1 - Symptomatic but Can Eat Regular Diet
2 - Dysphagia or Odynophagia Requiring Dietary Changes
3 - Need for Parenteral Nutrition

30. Nausea and vomiting:*(NAUSVOMT)*

0 - No Protracted Nausea and Vomiting
1 - Persistent Nausea, Vomiting or Anorexia

31. Diarrhea:*(CGVDIARH)*

0 - None
1 - Persisting Less Than 2 Weeks
2 - Persisting More Than 2 Weeks

32. Was diarrhea measured as number of stools or volume of stools?*(DIARHMSR)*

1 - Number of Stools
2 - Volume of Stools
3 - Both Number and Volume

33. Diarrhea (number of stools):*(DIARHEA1)*

1 - Increase of <4 Stools/day Over Baseline; Mild Increase in Ostomy Output Compared to Baseline
2 - Increase of 4-6 stools/day; IV Fluids Indicated <24 Hrs; Moderate Increase in Ostomy Output
3 - Increase of 7 or More Stools/day, IV Fluids for 24 or More Hrs; Hospitalization
4 - Life-threatening Consequences (e.g. Hemodynamic Collapse)
5 - Death

Use mL/day for adult recipients and mL/m^2 for pediatric recipients.

34. Diarrhea (volume of stools):*(DIARHEA2)*

1 - Diarrhea Less Than or Equal to 500 mL/day or <280 mL/m^2
2 - Diarrhea >500 but Less Than or Equal to 1000 mL/day or 280-555 mL/m^2
3 - Diarrhea >1000 but Less Than or Equal to 1500 mL/day or 556-833 mL/m^2
4 - Diarrhea >1500 mL/day or >833 mL/m^2
5 - Severe Abdominal Pain with or without Ileus, or Stool with Frank Blood or Melena

35. Malabsorption:*(MALABSRP)*

0 - No Symptoms
2 - Altered Diet; Oral Therapies Indicated (e.g. Enzymes, Medications, Dietary Supplements)
3 - Inability to Ailment Adequately via GI Tract (e.g. TPN Indicated)
4 - Life-threatening Consequences
5 - Death

Hepatic

36. Bilirubin level:*(LIVERBIL)*

0 - Bilirubin <2.0 mg/dL
1 - Bilirubin 2.0-3.0 mg/dL
2 - Bilirubin 3.1-6.0 mg/dL
3 - Bilirubin 6.1-15.0 mg/dL
4 - Bilirubin >15.0 mg/dL

Genitourinary

37. Vaginitis:*(VAGNITIS)*

0 - No Symptoms or Not Applicable
1 - Mild, Intervention Not Indicated
2 - Moderate, Intervention Indicated
3 - Severe, Not Relieved with Treatment; Ulceration

Musculoskeletal

38. Contractures:*(CONTRCTR)*

0 - No Symptoms
2 - Mild Joint Contractures (Does not Affect ADL)
3 - Severe Joint Contractures (Interferes with ADL)

39. Myositis:*(MYOSITIS)*

☐ 1 - Yes ☐ 2 - No

Hematologic

40. Eosinophilia:*(EOSINPHL)*

☐ 1 - Yes ☐ 2 - No

Other

41. Serositis:*(SEROSITS)* ☐ 1 - Yes ☐ 2 - No

42. Fascitis:*(FASCITIS)* ☐ 1 - Yes ☐ 2 - No

43. Was there other organ involvement?*(ORGNOTHR)* ☐ 1 - Yes ☐ 2 - No

Specify other organ:*(ORGSPEC)* _____

Answer questions 44-50 relating to biopsies performed during this assessment period.

44. Were any biopsies performed during this assessment period for suspected GVHD?*(BIOPSY)* ☐ 1 - Yes ☐ 2 - No

If yes, record the type, date, and result of any biopsies performed for suspected GVHD below.

Type of Biopsy:	If Other, Specify:	Date of Biopsy:	Result of Biopsy:
45. *(BIOTYP1)* 1 - Skin Biopsy 2 - Oral Biopsy 3 - Upper GI Biopsy 4 - Lower GI Biopsy 5 - Liver Biopsy *Additional Options Listed Below	*(TYP1OSPE)*	*(BIODT1)* _____ *(mm/dd/yyyy)*	*(BIORSLT1)* 1 - Positive 2 - Negative 3 - Equivoca
46. *(BIOTYP2)* 1 - Skin Biopsy 2 - Oral Biopsy 3 - Upper GI Biopsy 4 - Lower GI Biopsy 5 - Liver Biopsy *Additional Options Listed Below	*(TYP2OSPE)*	*(BIODT2)* _____ *(mm/dd/yyyy)*	*(BIORSLT2)* 1 - Positive 2 - Negative 3 - Equivoca
47. *(BIOTYP3)* 1 - Skin Biopsy 2 - Oral Biopsy 3 - Upper GI Biopsy 4 - Lower GI Biopsy 5 - Liver Biopsy *Additional Options Listed Below	*(TYP3OSPE)*	*(BIODT3)* _____ *(mm/dd/yyyy)*	*(BIORSLT3)* 1 - Positive 2 - Negative 3 - Equivoca
48. *(BIOTYP4)* 1 - Skin Biopsy 2 - Oral Biopsy 3 - Upper GI Biopsy 4 - Lower GI Biopsy 5 - Liver Biopsy *Additional Options Listed Below	*(TYP4OSPE)*	*(BIODT4)* _____ *(mm/dd/yyyy)*	*(BIORSLT4)* 1 - Positive 2 - Negative 3 - Equivoca
49. *(BIOTYP5)* 1 - Skin Biopsy 2 - Oral Biopsy 3 - Upper GI Biopsy 4 - Lower GI Biopsy 5 - Liver Biopsy *Additional Options Listed Below	*(TYP5OSPE)*	*(BIODT5)* _____ *(mm/dd/yyyy)*	*(BIORSLT5)* 1 - Positive 2 - Negative 3 - Equivoca
50. *(BIOTYP6)* 1 - Skin Biopsy 2 - Oral Biopsy 3 - Upper GI Biopsy 4 - Lower GI Biopsy 5 - Liver Biopsy *Additional Options Listed Below	*(TYP6OSPE)*	*(BIODT6)* _____ *(mm/dd/yyyy)*	*(BIORSLT6)* 1 - Positive 2 - Negative 3 - Equivoca

Answer questions 51-54 relating to GVHD therapy.

51. Was a specific therapy used to **treat** GVHD during this assessment period?*(THRPYUSD)*

1 - Yes, Initiated this Assessment Period
2 - Yes, Continuing from Previous Assessment Period
3 - No

?

If yes, indicate whether or not the agents listed below were used to **treat** GVHD during this assessment period:

a. ALS, ALG, ATS, ATG:*(THRPYATG)*

b. Azathioprine:*(THRPYAZA)*

c. Cyclosporine:*(THRPYCYC)*

d. Systemic Corticosteroids:*(THRPYSCO)*

e. Topical Corticosteroids:*(THRPYTCO)*

f. Thalidomide:*(THRPYTHA)*

g. Tacrolimus (FK 506, Prograf):*(THRPYTAC)*

h. Mycophenolate Mofetil (MMF, Cellcept):*(THRPYMMF)*

i. PUVA (Psoralen and UVA):*(THRPYPUV)*

j. ECP (Extra-corporeal Photopheresis):*(THRPYECP)*

k. Sirolimus (Rapamycin):*(THRPYSIR)*

l. Etretinate:*(THRPYETR)*

m. Lamprene:*(THRPYLAM)*

n. Etanercept:*(THRPYETA)*

o. Zenapax (Daclizumab):*(THRPYZEN)*

p. Chloroquine Phosphate:*(THRPYCPH)*

1 - Yes, Still Taking Drug
2 - Yes, No Longer Taking Drug
3 - No, Drug Not Given

q. In Vivo Anti T-lymphocyte Monoclonal Antibody: *(THRPYMAB)*

1 - Yes, Still Taking Drug
2 - Yes, No Longer Taking Drug
3 - No, Drug Not Given

Specify in vivo anti T-lymphocyte monoclonal antibody used: *(MABAGNT)*

r. In Vivo Immunotoxin: *(THRPYIMM)*

1 - Yes, Still Taking Drug
2 - Yes, No Longer Taking Drug
3 - No, Drug Not Given

Specify in vivo immunotoxin used: *(IMMAGNT)*

s. Other: *(THRPYOTH)*

1 - Yes, Still Taking Drug
2 - Yes, No Longer Taking Drug
3 - No, Drug Not Given

Specify other agent used: *(OTHAGNT)*

52. Has treatment been discontinued? *(ONGTRT)* ☐ 1 - Yes ☐ 2 - No

53. If yes, enter date of discontinuation: *(TRTSTOP)* *(mm/dd/yyyy)*

54. Indicate the best response to GVHD therapy during this assessment period: *(THRPYRSP)*

1 - Complete Resolution of Symptoms
2 - Partial Resolution of Symptoms
3 - Stable Symptoms
4 - Progression of Symptoms

?

Answer questions 55-58 relating to current patient status.

55. Are symptoms of GVHD still present? *(GVHDSYMP)* ☐ 1 - Yes ☐ 2 - No

56. Current Karnofsky/Lansky Score: *(CURKRNLN)*

01 - 100 (Normal; No Complaints/Fully Active)
02 - 90 (Normal Activity/Minor Restriction in Strenuous Play)
03 - 80 (Normal Activity with Effort/Restricted in Strenuous Play)
04 - 70 (Unable to Carry On Normal Activity/Less Time Spent in Play)
05 - 60 (Requires Occasional Assistance/Minimal Active Play)
*Additional Options Listed Below

57. Current platelet count: *(CURPLTCT)* *(xxx.x)* x 10^9/L

58. Current weight: *(CURWGHT)* *(xxx.x)* kg

Comments: *(CGVCOMM)*

Additional Selection Options for CGV

Minimum Karnofsky/Lansky Score at time of diagnosis:
06 - 50 (Requires Considerable Assistance/No Active Play)
07 - 40 (Disabled/Able to Initiate Quiet Activities)
08 - 30 (Severely Disabled/Needs Assistance for Quiet Play)
09 - 20 (Very Sick/Limited to Very Passive Activity)
10 - 10 (Moribund; Completely Disabled)

Biopsy Type 1
6 - Lung Biopsy
7 - Other, Specify

Current Karnofsky/Lansky Score:
06 - 50 (Requires Considerable Assistance/No Active Play)
07 - 40 (Disabled/Able to Initiate Quiet Activities)
08 - 30 (Severly Disabled/Needs Assistance for Quiet Play)
09 - 20 (Very Sick/Limited to Very Passive Activity)
10 - 10 (Moribund; Completely Disabled)
11 - 0 (Dead)

Blood and Marrow Transplant Clinical Trials Network

Cord Blood HLA (CH1)

Web Version: 1.0; 4.01; 04-07-10

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

HLA Typing

Type of HLA Match required by this protocol:*(HLAMATCH)*

- LociA,B:Low LevelDNA,Locus DRB1:High LevelDNA
- LociA,B:Serologic,Locus DRB1:High LevelDNA
- LociA,B:Serologic,Locus DRB1:Low LevelDNA
- LociA,B,C:Low LevelDNA,Locus DRB1:High LevelDNA
- LociA,B,C:Serologic,Locus DRB1:High LevelDNA
- *AdditionalOptions Listed Below

1. Recipient HLA Typing

HLA-A

Typing method:*(HLAAMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLAANUM)*

- 1 - One
- 2 - Two

1st:	*(HLAA11X)*		*(HLAA12X)* /		*(HLAA13X)* /		*(HLAA14X)* /
	(HLAA15X)		*(HLAA16X)* /		*(HLAA17X)* /		*(HLAA18X)* /
2nd:	*(HLAA21X)*		*(HLAA22X)* /		*(HLAA23X)* /		*(HLAA24X)* /
	(HLAA25X)		*(HLAA26X)* /		*(HLAA27X)* /		*(HLAA28X)* /

HLA-B

Typing method:*(HLABMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLABNUM)*

- 1 - One
- 2 - Two

1st:	*(HLAB11X)*		*(HLAB12X)* /		*(HLAB13X)* /		*(HLAB14X)* /
	(HLAB15X)		*(HLAB16X)* /		*(HLAB17X)* /		*(HLAB18X)* /
2nd:	*(HLAB21X)*		*(HLAB22X)* /		*(HLAB23X)* /		*(HLAB24X)* /
	(HLAB25X)		*(HLAB26X)* /		*(HLAB27X)* /		*(HLAB28X)* /

HLA-DRB1

Typing method:*(HLADMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLADNUM)*

- 1 - One
- 2 - Two

1st:	*(HLAD11X)*		*(HLAD12X)* /		*(HLAD13X)* /		*(HLAD14X)* /
	(HLAD15X)		*(HLAD16X)* /		*(HLAD17X)* /		*(HLAD18X)* /
2nd:	*(HLAD21X)*		*(HLAD22X)* /		*(HLAD23X)* /		*(HLAD24X)* /
	(HLAD25X)		*(HLAD26X)* /		*(HLAD27X)* /		*(HLAD28X)* /

Comments:*(CH1COMM)*

Additional Selection Options for CH1

Type of HLA Match required by this protocol:
Loci A, B, C, DQ: Low Level DNA, Locus DRB1: High Level DNA
High Level DNA
Low Level DNA
Serologic

Blood and Marrow Transplant Clinical Trials Network

Cord Blood HLA (Page 2) (CH2)

Web Version: 1.0; 4.02; 04-07-10

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

HLA Typing

Type of HLA Match required by this protocol:*(HLAMATCH)*

- LociA,B:Low LevelDNA,Locus DRB1:High LevelDNA
- LociA,B:Serologic,Locus DRB1:High LevelDNA
- LociA,B:Serologic,Locus DRB1:Low LevelDNA
- LociA,B,C:Low LevelDNA,Locus DRB1:High LevelDNA
- LociA,B,C:Serologic,Locus DRB1:High LevelDNA
- *AdditionalOptionsListedBelow

1. First Cord Blood Unit HLA Typing

Bank ID:*(HCB1BKID)*

HLA-A

Typing method:*(HLAAMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLAANUM)*

- 1 - One
- 2 - Two

1st:	*(HLAA11X)*		*(HLAA12X)* /		*(HLAA13X)* /		*(HLAA14X)* /
	(HLAA15X)		*(HLAA16X)* /		*(HLAA17X)* /		*(HLAA18X)* /
2nd:	*(HLAA21X)*		*(HLAA22X)* /		*(HLAA23X)* /		*(HLAA24X)* /
	(HLAA25X)		*(HLAA26X)* /		*(HLAA27X)* /		*(HLAA28X)* /

HLA-B

Typing method:*(HLABMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLABNUM)*

- 1 - One
- 2 - Two

1st:	*(HLAB11X)*		*(HLAB12X)* /		*(HLAB13X)* /		*(HLAB14X)* /
	(HLAB15X)		*(HLAB16X)* /		*(HLAB17X)* /		*(HLAB18X)* /
2nd:	*(HLAB21X)*		*(HLAB22X)* /		*(HLAB23X)* /		*(HLAB24X)* /
	(HLAB25X)		*(HLAB26X)* /		*(HLAB27X)* /		*(HLAB28X)* /

HLA-DRB1

Typing method:*(HLADMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLADNUM)*

- 1 - One
- 2 - Two

1st:	*(HLAD11X)*		*(HLAD12X)* /		*(HLAD13X)* /		*(HLAD14X)* /
	(HLAD15X)		*(HLAD16X)* /		*(HLAD17X)* /		*(HLAD18X)* /
2nd:	*(HLAD21X)*		*(HLAD22X)* /		*(HLAD23X)* /		*(HLAD24X)* /
	(HLAD25X)		*(HLAD26X)* /		*(HLAD27X)* /		*(HLAD28X)* /

Comments:*(CH2COMM)*



Additional Selection Options for CH2

Type of HLA Match required by this protocol:
Loci A, B, C, DQ: Low Level DNA, Locus DRB1: High Level DNA
High Level DNA
Low Level DNA
Serologic

Blood and Marrow Transplant Clinical Trials Network

Cord Blood HLA (Page 3) (CH3)

Web Version: 1.0; 4.02; 04-07-10

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

HLA Typing

Type of HLA Match required by this protocol:*(HLAMATCH)*

- Loci A, B: Low Level DNA, Locus DRB1: High Level DNA
- Loci A, B: Serologic, Locus DRB1: High Level DNA
- Loci A, B: Serologic, Locus DRB1: Low Level DNA
- Loci A, B, C: Low Level DNA, Locus DRB1: High Level DNA
- Loci A, B, C: Serologic, Locus DRB1: High Level DNA
- *Additional Options Listed Below

1. Second Cord Blood Unit HLA Typing

Bank ID:*(HCB2BKID)*

HLA-A

Typing method:*(HLAAMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLAANUM)*

- 1 - One
- 2 - Two

1st:	*(HLAA11X)*		*(HLAA12X)* /		*(HLAA13X)* /		*(HLAA14X)* /
	(HLAA15X)		*(HLAA16X)* /		*(HLAA17X)* /		*(HLAA18X)* /
2nd:	*(HLAA21X)*		*(HLAA22X)* /		*(HLAA23X)* /		*(HLAA24X)* /
	(HLAA25X)		*(HLAA26X)* /		*(HLAA27X)* /		*(HLAA28X)* /

HLA-B

Typing method:*(HLABMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLABNUM)*

- 1 - One
- 2 - Two

1st:	*(HLAB11X)*		*(HLAB12X)* /		*(HLAB13X)* /		*(HLAB14X)* /
	(HLAB15X)		*(HLAB16X)* /		*(HLAB17X)* /		*(HLAB18X)* /
2nd:	*(HLAB21X)*		*(HLAB22X)* /		*(HLAB23X)* /		*(HLAB24X)* /
	(HLAB25X)		*(HLAB26X)* /		*(HLAB27X)* /		*(HLAB28X)* /

HLA-DRB1

Typing method:*(HLADMET)*

- 1 - DNA Technology
- 2 - Serology

Antigens/alleles provided:*(HLADNUM)*

- 1 - One
- 2 - Two

1st:	*(HLAD11X)*		*(HLAD12X)* /		*(HLAD13X)* /		*(HLAD14X)* /
	(HLAD15X)		*(HLAD16X)* /		*(HLAD17X)* /		*(HLAD18X)* /
2nd:	*(HLAD21X)*		*(HLAD22X)* /		*(HLAD23X)* /		*(HLAD24X)* /
	(HLAD25X)		*(HLAD26X)* /		*(HLAD27X)* /		*(HLAD28X)* /

Recipient-to-First Cord Blood Unit HLA Match Scores

Recipient-to-First Cord Blood Unit HLA Match Score required by this protocol: *(CRD1HRQD)*

Recipient-to-First Cord Blood Unit *Locus-A* calculated HLA Match Score*(CRD1SCRA)*

Recipient-to-First Cord Blood Unit *Locus-B* calculated HLA Match Score*(CRD1SCRB)*

Recipient-to-First Cord Blood Unit *Locus-DRB1* calculated HLA Match Score*(CRD1SCRD)*

Recipient-to-First Cord Blood Unit *Total* calculated HLA Match Score*(CRD1HLA)*

Do you agree with the calculated HLA Match Score for Recipient-to-First Cord Blood Unit ?*(CRD1AGRE)* ☐ 1 - Yes ☐ 2 - No

Indicate your institution's HLA Match Score for Recipient-to-First Cord Blood Unit :*(CRD1SISC)*

0/6
1/6
2/6
3/6
4/6
*Additional Options Listed Below

Do you agree with the calculated HLA Match Score forRecipient-to-First Cord Blood Unit ?*(CRD1AGRE)* ☐ 1 - Yes ☐ 2 - No

Indicate your institution's HLA Match Score for Recipient-to-First Cord Blood Unit :*(CRD1SISC)*

0/6
1/6
2/6
3/6
4/6
*Additional Options Listed Below

Recipient-to-Second Cord Blood Unit HLA Match Scores

Recipient-to-Second Cord Blood Unit HLA Match Score required by this protocol:
(CRD2HRQD)

Recipient-to-Second Cord Blood Unit *Locus-A* calculated HLA Match Score *(CRD2SCRA)*

Recipient-to-Second Cord Blood Unit *Locus-B* calculated HLA Match Score *(CRD2SCRB)*

Recipient-to-Second Cord Blood Unit *Locus-DRB1* calculated HLA Match Score *(CRD2SCRD)*

Recipient-to-Second Cord Blood Unit *Total* calculated HLA Match Score *(CRD2HLA)*

Do you agree with the calculated HLA Match Score for Recipient-to-Second Cord Blood Unit ?
(CRD2AGRE) ☐ 1 - Yes ☐ 2 - No

Indicate your institution's HLA Match Score for Recipient-to-Second Cord Blood Unit :
(CRD2SISC)

0/6
1/6
2/6
3/6
4/6
*Additional Options Listed Below

Do you agree with the calculated HLA Match Score for Recipient-to-Second Cord Blood Unit ?
(CRD2AGRE) ☐ 1 - Yes ☐ 2 - No

Indicate your institution's HLA Match Score for Recipient-to-Second Cord Blood Unit :
(CRD2SISC)

0/6
1/6
2/6
3/6
4/6
*Additional Options Listed Below

First Cord Blood Unit-to-Second Cord Blood Unit HLA Match Scores

First Cord Blood Unit-to-Second Cord Blood Unit HLA Match Score required by this protocol:*(CRD3HRQD)*

First Cord Blood Unit-to-Second Cord Blood Unit *Locus-A* calculated HLA Match Score*(CRD3SCRA)*

First Cord Blood Unit-to-Second Cord Blood Unit *Locus-B* calculated HLA Match Score*(CRD3SCRB)*

First Cord Blood Unit-to-Second Cord Blood Unit *Locus-DRB1* calculated HLA Match Score*(CRD3SCRD)*

First Cord Blood Unit-to-Second Cord Blood Unit *Total* calculated HLA Match Score*(CRD3HLA)*

Do you agree with the calculated HLA Match Score for First Cord Blood Unit-to-Second Cord Blood Unit ?*(CRD3AGRE)* ☐ 1 - Yes ☐ 2 - No

Indicate your institution's HLA Match Score for First Cord Blood Unit-to-Second Cord Blood Unit:*(CRD3SISC)*

0/6
1/6
2/6
3/6
4/6
*Additional Options Listed Below

Do you agree with the calculated HLA Match Score for First Cord Blood Unit-to-Second Cord Blood Unit?*(CRD3AGRE)*

☐ 1 - Yes ☐ 2 - No

Indicate your institution's HLA Match Score for First Cord Blood Unit-to-Second Cord Blood Unit:*(CRD3SISC)*

0/6
1/6
2/6
3/6
4/6
*Additional Options Listed Below

Comments:*(CH3COMM)*

Additional Selection Options for CH3

Type of HLA Match required by this protocol:
Loci A, B, C, DQ: Low Level DNA, Locus DRB1: High Level DNA
High Level DNA
Low Level DNA
Serologic

Indicate your institution's HLA Match Score for Recipient-to-First Cord Blood Unit :
5/6
6/6
0/8
1/8
2/8
3/8
4/8
5/8
6/8
7/8
8/8

Blood and Marrow Transplant Clinical Trials Network

Demographics (DEM)

Web Version: 1.0; 6.02; 12-02-15

1. Name Code:*(NAMECODE)*
2. IUBMID # (if available):*(IUBMID)*
3. Gender:*(GENDER)* ☐ 1 - Male ☐ 2 - Female
4. Date of Birth:*(DOB)* *(mm/dd/yyyy)*
5. Ethnicity:*(ETHNIC)*

```
1-Hispanic or Latino
2-Not Hispanic or Latino
8-Unknown
9-Not Answered
```

6. Race:*(RACE)*

```
White
10-White (Not Otherwise Specified)
11-European (Not Otherwise Specified)
13-Mediterranean
14-White North American
*Additional Options Listed Below
```

Specify race:*(RACESP)*

7. Secondary Race:*(RACE2)*

```
White
10-White (Not Otherwise Specified)
11-European (Not Otherwise Specified)
13-Mediterranean
14-White North American
*Additional Options Listed Below
```

Specify secondary race:*(RACE2SP)*

Comments:*(DEMCOMM1)*

Additional Selection Options for DEM

Race:
15 - South or Central American
16 - Eastern European
17 - Northern European
18 - Western European
81 - White Caribbean
82 - North Coast of Africa
83 - Middle Eastern
Black
20 - Black (Not Otherwise Specified)
21 - African American
22 - African Black (Both Parents Born in Africa)
23 - Caribbean Black
24 - South or Central American Black
29 - Black, Other Specify
Asian
30 - Asian (Not Otherwise Specified)
31 - Indian/South Asian
32 - Filipino (Pilipino)
34 - Japanese
35 - Korean
36 - Chinese
37 - Other Southeast Asian
38 - Vietnamese
American Indian or Alaska Native
50 - Native American (Not Otherwise Specified)
51 - Native Alaskan/Eskimo/Aleut
52 - American Indian (Not Otherwise Specified)
53 - North American Indian
54 - South or Central American Indian
55 - Caribbean Indian
Native Hawaiian or Other Pacific Islander
60 - Native Pacific Islander (Not Otherwise Specified)
61 - Guamanian
62 - Hawaiian
63 - Samoan
Other
88 - Unknown
90 - Other, Specify
99 - Not Answered

Blood and Marrow Transplant Clinical Trials Network

Death Form (DTH)

Web Version: 1.0; 4.14; 11-05-15

1. Record date of death:*(DTHDT)* *(mm/dd/yyyy)*

2. Was an autopsy performed?*(AUTPERF)* ☐ 1 - Yes ☐ 2 - No

If yes, attach de-identified autopsy report or death summary to the form below.

Enter appropriate cause of death code below. List in order of decreasing severity.

3. Primary cause of death:*(CZDTHPRM)*

1.0 - Graft Rejection or Failure
Infection (Other than Interstitial Pneumonia)
1.1 - Autologous Recovery
1.2 - Rejection
2.1 - Bacterial
*Additional Options Listed Below

?

Specify other:*(DTHSPEC1)*

4. Secondary cause of death:*(SCNDCZ1)*

1.0 - Graft Rejection or Failure
Infection (Other than Interstitial Pneumonia)
1.1 - Autologous Recovery
1.2 - Rejection
2.1 - Bacterial
*Additional Options Listed Below

Specify other:*(DTHSPEC2)*

5. Secondary cause of death:*(SCNDCZ2)*

1.0 - Graft Rejection or Failure
Infection (Other than Interstitial Pneumonia)
1.1 - Autologous Recovery
1.2 - Rejection
2.1 - Bacterial
*Additional Options Listed Below

Specify other:*(DTHSPEC3)*

6. Secondary cause of death:*(SCNDCZ3)*

1.0 - Graft Rejection or Failure
Infection (Other than Interstitial Pneumonia)
1.1 - Autologous Recovery
1.2 - Rejection
2.1 - Bacterial
*Additional Options Listed Below

Specify other:*(DTHSPEC4)*

7. Secondary cause of death:*(SCNDCZ4)*

1.0 - Graft Rejection or Failure
Infection (Other than Interstitial Pneumonia)
1.1 - Autologous Recovery
1.2 - Rejection
2.1 - Bacterial
*Additional Options Listed Below

Specify other:*(DTHSPEC5)*

Comments:*(DTCMMNTS)*

Additional Selection Options for DTH

Primary cause of death:
2.2 - Fungal
2.3 - Viral
2.4 - Protozoal
2.5 - Other, Specify Below
2.9 - Organism Not Identified
Interstitial Pneumonia
3.1 - Viral, CMV
3.2 - Viral, Other
3.3 - Pneumocystis
3.4 - Other, Specify Below
3.9 - Idiopathic
4.0 - Adult Respiratory Distress Syndrome
5.0 - Acute GVHD
6.0 - Chronic GVHD
7.0 - Recurrence or Persistence of Leukemia/Malignancy/MDS
7.1 - Persistent Disease
Organ Failure (Not Due to GVHD or Infection)
8.1 - Liver
8.2 - Cardiac (Cardiomyopathy)
8.3 - Pulmonary
8.4 - CNS
8.5 - Renal
8.6 - Other, Specify Below
8.7 - Multiple Organ Failure, Specify Below
8.8 - Secondary Graft Failure
9.0 - Secondary Malignancy
9.1 - EBV
9.2 - Other, Specify Below
Hemorrhage
10.1 - Pulmonary
10.2 - Intracranial
10.3 - Gastrointestinal
10.4 - Hemorrhage Not Specified
10.5 - Other, Specify Below
Vascular
11.1 - Thromboembolic
11.2 - Disseminated Intravascular Coagulation (DIC)
11.3 - Gastrointestinal
11.4 - Thrombotic Thrombocytopenic Purpura
11.5 - Vascular Not Specified
11.9 - Other, Specify Below
12.0 - Accidental Death
13.0 - Other, Specify Below

Blood and Marrow Transplant Clinical Trials Network

0501A (ENR)

Web Version: 1.0; 10.00; 06-14-12

1. Record date patient informed consent form signed:*(CSTDTCB)* _____ *(mm/dd/yyyy)*
2. Patient's date of birth:*(PTSDOBCB)* 01/12/1976 *(mm/dd/yyyy)*
3. Patient's body weight:*(PTSWGTCB)* _____ *(xxx.x)* kg
4. Record date patient's body weight was obtained:*(PTSWGTDT)* _____ *(mm/dd/yyyy)*

If patient is registered with COG, enter COG ID number below.

5. COG Patient ID number:*(COGID)* _____

Inclusion Criteria

6. Proposed conditioning start date:*(CONDSTDT)* _____ *(mm/dd/yyyy)*
7. Date of most recent bone marrow aspirate:*(ASPIRTDT)* _____ *(mm/dd/yyyy)*
8. Does the patient have two partially HLA-matched cord blood units?*(HLACRDUN)* ☐ 1 - Yes ☐ 2 - No
9. Record the patient's primary disease:*(PRIMDIS)*

```
1 - Acute Myelogenous Leukemia (AML)
2 - Acute Lymphoblastic Leukemia (ALL)
3 - Acute Biphenotypic Leukemia
4 - Acute Undifferentiated Leukemia (AUL)
5 - Myelodysplastic Syndrome (MDS)
*Additional Options Listed Below
```

10. If AML, record disease stage:*(AMLDXSTG)*

```
1 - 1st Complete Remission
2 - Complete Remission Greater Than or Equal to 2nd CR
3 - First Relapse
4 - Morphologic Complete Remission with Incomplete Blood Count Recovery
```

11. Did the patient have preceding myelodysplasia (MDS)?*(PREMDS)* ☐ 1 - Yes ☐ 2 - No
12. Does the patient have high risk cytogenetics?*(CYTORSK)* ☐ 1 - Yes ☐ 2 - No

High-risk cytogenetics: del (5q) -5, -7, abn (3q), t (6;9) complex karyotype (≥5 abnormalities).

13. Did the patient require > 1 cycles of chemotherapy to obtain complete remission?*(CHEMOCR)* ☐ 1 - Yes ☐ 2 - No
14. If in first relapse, record percent blasts in the bone marrow:*(AMLBLST)* _____ *(xx.x)* %
15. Indicate the FAB classification:*(FABCB)*

```
0 - M0 - Minimally differentiated acute myeloblastic leukemia
1 - M1 - Acute myeloblastic leukemia, without maturation
2 - M2 - Acute myeloblastic leukemia, with granulocyte maturation
3 - M3 - acute promyelocytic leukemia
4 - M4 - Acute myelomonocytic leukemia
*Additional Options Listed Below
```

16. If ALL, record disease stage:*(ALLDXSTG)*

```
1 - First Remission
2 - Second Remission
3 - Subsequent Remission
4 - Morphologic Complete Remission with Incomplete Blood Count Recovery
```

17. Is the patient PH+?*(PTPHPOS)* ☐ 1 - Yes ☐ 2 - No
18. Does the patient have MLL rearrangement with slow early response? *(MLLREARR)* ☐ 1 - Yes ☐ 2 - No

Defined as having M2 (5-25% blasts) or M3 (>25% blasts on bone marrow examination on Day 14 of induction therapy).

19. Does the patient have hypodiploidy (< 44 chromosomes or DNA index < 0.81)?*(HYPODIP)* ☐ 1 - Yes ☐ 2 - No
20. At the end of induction, did the patient have a M3 bone marrow? *(ENDINDMT)* ☐ 1 - Yes ☐ 2 - No
21. At the end of induction, did the patient have a M2 bone marrow and at Day 42, a M2 or M3 bone marrow?*(ENDINDMS)* ☐ 1 - Yes ☐ 2 - No
22. Did the patient have a bone marrow relapse < 36 months from induction? *(BMRLPS)* ☐ 1 - Yes ☐ 2 - No
23. Did the patient have a T-lineage relapse at any time?*(TLRLPS)* ☐ 1 - Yes ☐ 2 - No
24. Did the patient have early isolated CNS relapse within 6 months of diagnosis?*(CNSRLPS)* ☐ 1 - Yes ☐ 2 - No

25. Did the patient have slow reinduction (M2-3 at Day 28) after any relapse? *(SLWREIND)* ☐ 1 - Yes ☐ 2 - No

26. Does the patient have evidence of MRD? *(ALLMRD)* ☐ 1 - Yes ☐ 2 - No

27. Is evidence of MRD the patient's only high risk criteria? *(MRDONLY)* ☐ 1 - Yes ☐ 2 - No

28. Record the date of protocol chair or protocol officer approval: *(MRDAPVDT)* _____ *(mm/dd/yyyy)*

29. If biphenotypic or undifferentiated leukemia, record disease stage: *(BIPDXSTG)*

1 - 1st Complete Remission
2 - 2nd Complete Remission
3 - 3rd Complete Remission
4 - Complete Remission > 3rd CR
5 - First Relapse
*Additional Options Listed Below

30. If in first relapse, record percent blasts in the bone marrow: *(BMBLST)* _____ *(xx.x)* %

31. If MDS, record disease stage: *(MDSDXSTG)*

1 - Refractory Anemia
2 - Refractory Anemia with Ringed Sideroblasts
3 - Refractory Cytopenia with Multilineage Dysplasia
4 - Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts
5 - Refractory Anemia with Excess Blasts - 1 (5-10% blasts)
*Additional Options Listed Below

32. If CML, record disease stage: *(CMLDXSTG)*

1 - 1st Chronic Phase
2 - 2nd Chronic Phase
3 - 3rd or Greater Chronic Phase
4 - Accelerated Phase

33. If secondary/ therapy related AML, has the prior malignancy been in remission for at least 12 months? *(PREREMSN)* ☐ 1 - Yes ☐ 2 - No

34. If the patient has evidence of CNS leukemia, is it now in complete remission? *(CNSCR)* ☐ 1 - Yes ☐ 2 - No ☐ 3 - Not Applicable

35. Performance status scale used to evaluate patient (Lansky for patients < 16 years old; Karnofsky for patients ≥ 16): *(PRFSCL)* ☐ 1 - Karnofsky ☐ 2 - Lansky

36. Record patient's performance status: *(PRFSTCB)*

01 - 100 (Normal; No Complaints/Fully Active)
02 - 90 (Normal Activity/Minor Restriction in Strenuous Play)
03 - 80 (Normal Activity with Effort/Restricted in Strenuous Play)
04 - 70 (Unable to Carry On Normal Activity/Less Time Spent in Play)
05 - 60 (Requires Occasional Assistance/Minimal Active Play)
*Additional Options Listed Below

37. Record the type of fraction test performed: *(TYPFRCTX)*

1 - Left Ventricular Ejection Fraction (LVEF)
2 - Shortening Fraction

38. Record LVEF at rest: *(RSTLVEF)* _____ *(xxx)* % Date ejection fraction performed: *(DTLVEF)* _____ *(mm/dd/yyyy)*

39. Record shortening fraction at rest: *(SHFRCRST)* _____ *(xxx)* % Date shortening fraction performed: *(SHRFCDT)* _____ *(mm/dd/yyyy)*

	Most Recent Value	LLN for your Institution	ULN for your Institution	Date Sample Obtained
40. Creatinine (mg/dL):	*(CRTRVCB)* _____ *(x.x)*	*(CRTLLNCB)* _____ *(x.x)*	*(CRTULNCB)* _____ *(x.x)*	*(CRTDATCB)* _____ *(mm/dd/yyyy)*
41. Creatinine Clearance (mL/min):	*(CCLRRVCB)* _____ *(xxx)*	*(CCLRLNCB)* _____ *(xxx)*	N/A	*(CCLRDTCB)* _____ *(mm/dd/yyyy)*
42. ALT (Units/L):	*(ALTRVCB)* _____ *(xxx)*	N/A	*(ALTULNCB)* _____ *(xxx)*	*(ALTDTCB)* _____ *(mm/dd/yyyy)*
43. AST (Units/L):	*(ASTRVCB)* _____ *(xxx)*	N/A	*(ASTULNCB)* _____ *(xxx)*	*(ASTDTCB)* _____ *(mm/dd/yyyy)*
44. Alkaline Phosphatase (Units/L):	*(ALPRVCB)* _____ *(xxx)*	N/A	*(ALPULNCB)* _____ *(xxx)*	*(ALPDTCB)* _____ *(mm/dd/yyyy)*
45. Bilirubin (mg/dL):	*(BILIRVCB)* _____ *(x.x)*	N/A	N/A	*(BILIDTCB)* _____ *(mm/dd/yyyy)*

46. What tests were performed to determine pulmonary function? *(PFT2TXCB)*

1 - PFTs (DLCO, FEV1 and FVC)
2 - Oxygen Saturation
3 - Oxygen Saturation, FEV1, and FVC

If PFT's were not performed, then an O_2 saturation must be obtained.

	Most Recent Value Corrected for Hemoglobin	Date Sample Obtained
47. DLCO:	*(DLCORVCB)* *(xxx)* % of predicted value	*(DLCODTCB)* *(mm/dd/yyyy)*
48. FEV1:	*(FEVRVCB)* *(xxx)* % of predicted value	*(FEVDTCB)* *(mm/dd/yyyy)*
49. FVC:	*(FECRVCB)* *(xxx)* % of predicted value	*(FECDTCB)* *(mm/dd/yyyy)*

50. O_2 saturation on room air:*(OXSATCB)* *(xxx)* % Date O_2 saturation was obtained*(OXSTDT)* *(mm/dd/yyyy)*

Exclusion Criteria

51. Is the patient pregnant (positive β-HCG) or breastfeeding?*(PRGNTCB)* 1 - Yes 2 - No 3 - Not Applicable
52. Does the patient have evidence of HIV infection or have HIV positive serology? *(HIVPSTCB)* 1 - Yes 2 - No
53. Does the patient have a current uncontrolled bacterial, viral, or fungal infection (currently taking medication and progression of clinical symptoms)?*(VFBACINF)* 1 - Yes 2 - No
54. Has the patient had a prior autologous transplant?*(PRIORAUT)* 1 - Yes 2 - No
    55. Date of most recent autologous transplant:*(AUTTRDT)* *(mm/dd/yyyy)*
    56. Was the disease for which the prior autologous transplant performed the same as the disease for which the UCB transplant will be performed?*(DXINDCB)* 1 - Yes 2 - No
57. Has the patient had a prior allogeneic hematopoietic stem cell transplant? *(PRIORALO)* 1 - Yes 2 - No
58. Has the patient had an active malignancy within the last 12 months (other than the one for which this transplant is being performed)?*(ACTMALG)* 1 - Yes 2 - No
59. Is the patient unable to receive TBI?*(PTTBICB)* 1 - Yes 2 - No
60. Does the patient require supplemental oxygen?*(PTSUPOX)* 1 - Yes 2 - No
61. Does the patient have an HLA-matched related donor able to donate?*(HLAMTCB)* 1 - Yes 2 - No

Consent for Use of Biological Specimens for Research

62. Did the patient (or if the patient is a minor, the parent/ legal guardian) give consent to have blood drawn for research purposes?*(RSCHBLD)* 1 - Yes 2 - No

Cord Blood Units

Enter the unique ID for each cord blood unit below. Do NOT enter the ID for the bank that the cord blood unit came from. Do not include dashes or spaces in the ID.

	First Cord Blood Unit	Second Cord Blood Unit
63. Bank Identification Number:	*(FSTCRDID)*	*(SNDCRDID)*
64. Pre-cryopreservation total nucleated cell count:	*(FPRNUCDS)* *(xx.x)* x 10^8 NC	*(SPRNUCDS)* *(xx.x)* x 10^8 NC
65. Nucleated cell dose:	*(FRSTNUC)* *(xx.x)* x 10^7 NC/kg	*(SNDNUC)* *(xx.x)* x 10^7 NC/kg
66. HLA-match level between the patient and the cord blood unit:	*(FRSTCORD)* 0/6 1/6 2/6 3/6 4/6 *Additional Options Listed Below	*(SCNDCORD)* 0/6 1/6 2/6 3/6 4/6 *Additional Options Listed Below
67. Indicate whether the UCB unit is a licensed unit, under IND at transplant centers own institution or under an IND held at another institution:	*(UCB1IND)* 1 - Licensed UCB Unit 2 - Under IND at Clinical Center 3 - Under IND at NMDP 4 - Center Outside of the US	*(UCB2IND)* 1 - Licensed UCB Unit 2 - Under IND at Clinical Center 3 - Under IND at NMDP 4 - Center Outside of the US

68. Record HLA match of the two cord blood units to each other:*(TWOCORD)* 0/6 1/6 2/6 3/6 4/6 *Additional Options Listed Below

Comments:*(CMMNTSCB)*

Additional Selection Options for ENR

Record the patient's primary disease:
6 - Chronic Myelogenous Leukemia (CML)
7 - Secondary/ Therapy Related AML
8 - NK Cell Lymphoblastic Leukemia

Indicate the FAB classification:
5 - M5 - Acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b)
6 - M6 - Acute erythroid leukemias
7 - M7 - Acute megakaryoblastic leukemia
9 - Unknown

If biphenotypic or undifferentiated leukemia, record disease stage:
6 - Morphologic Complete Remission with Incomplete Blood Count Recovery

If MDS, record disease stage:
6 - Refractory Anemia with Excess Blasts - 2 (10-20% blasts)
7 - Myelodysplastic Syndrome, Unclassified
8 - MDS Associated with Isolated Del(5q)

Record patient's performance status:
06 - 50 (Requires Considerable Assistance/No Active Play)
07 - 40 (Disabled/Able to Initiate Quiet Activities)
08 - 30 (Severely Disabled/Needs Assistance for Quiet Play)
09 - 20 (Very Sick/Limited to Very Passive Activity)
10 - 10 (Moribund; Completely Disabled)

Match 1st Cord Bld
5/6
6/6

Blood and Marrow Transplant Clinical Trials Network

Follow Up Status Form (FUS)

Web Version: 1.0; 12.01; 10-16-15

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

1. Date of last contact:*(LASTCTDT)* *(mm/dd/yyyy)*

Since the date of the last visit indicate if any of the following have occurred:

2. Has the patient died?*(DIED)* ☐ 1 - Yes ☐ 2 - No
If Yes, a Death Form must be submitted.

3. Date of patient death:*(DEATHDT)* *(mm/dd/yyyy)*

4. Has the patient relapsed or experienced disease progression?*(RELAPSE)* ☐ 1 - Yes ☐ 2 - No
If Yes, a Relapse Form must be submitted.

5. Date of relapse or progression:*(RELAPSDT)* *(mm/dd/yyyy)*

6. Has the patient been treated for progression/relapse?*(RELAPSTX)* ☐ 1 - Yes ☐ 2 - No

7. Date treatment administered:*(TREATDT)* *(mm/dd/yyyy)*

8. Indicate type of treatment:*(TREATYPE)*

1 - DLI
2 - PBSCs
3 - Chemotherapy
4 - Radiation
5 - Second Transplant
*Additional Options Listed Below

Specify other treatment:*(FUS1SPEC)*

9. Has the patient experienced secondary graft failure?*(SECGRFAL)* ☐ 1 - Yes ☐ 2 - No

10. Has the patient experienced secondary graft failure?*(SECGRFAL)* ☐ 1 - Yes ☐ 2 - No
If Yes, a Secondary Graft Failure Form must be submitted.

11. Date of secondary graft failure:*(SCGRFLDT)* *(mm/dd/yyyy)*

12. Date of secondary graft failure:*(SCGRFLDT)* *(mm/dd/yyyy)*

13.

14. Has the patient experienced any new clinically significant infections?*(NEWINFX)* ☐ 1 - Yes ☐ 2 - No
If Yes, an Infection Form must be submitted.

15. Date of infection:*(INFDT)* *(mm/dd/yyyy)*

16. Has the patient been hospitalized?*(HOSPITAL)* ☐ 1 - Yes ☐ 2 - No
If Yes, a Re-Admission Form must be submitted.

17. Date of hospitalization:*(HOSPTLDT)* *(mm/dd/yyyy)*

18. Has the patient received a non-protocol specified transplant?*(TRANSTWO)* ☐ 1 - Yes ☐ 2 - No

19. Date of non-protocol specified transplant:*(DATRANSP)* *(mm/dd/yyyy)*

Comments:*(FUS1COMM)*

Additional Selection Options for FUS

Indicate type of treatment:
6 - Other Cellular Therapy
7 - Other

Blood and Marrow Transplant Clinical Trials Network

Acute GVHD Form (GVH)

Web Version: 1.0; 10.11; 10-16-15

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

1. Date of staging:*(STAGEDT)* *(mm/dd/yyyy)*

   Start of GVHD Assessment Period:*(GVASSTDT)* *(mm/dd/yyyy)*

   End of GVHD Assessment Period:*(GVASENDT)* *(mm/dd/yyyy)*

   The assessment for which you are entering data must have taken place within the above dates. If the patient was not seen during the assessment period specified above, please exit the form and request an exception for this form.

2. Immunosuppressant (prophylaxis) received:*(IMMUNORC)*

   0 - Prednisone
   1 - Cyclosporine
   2 - Tacrolimus
   3 - Not taken during assessment

3. Record most recent blood level of immunosuppressant (prophylaxis): *(TROUGHLV)* *(xxxx.x)* ng/mL

4. Record date blood sample obtained:*(TROUGHDT)* *(mm/dd/yyyy)*

Record the highest level of organ abnormalities, the etiologies contributing to the abnormalities and any biopsy results during the assessment period.

5. Skin abnormalities:*(GVHSKINA)*

   0 - No Rash
   1 - Maculopapular Rash, <25% of Body Surface
   2 - Maculopapular Rash, 25-50% of Body Surface
   3 - Generalized Erythroderma
   4 - Generalized Erythroderma with Bullus Formation and Desquamation

6. Skin etiologies:

GVHD	Drug Reaction	Conditioning Regimen Toxicity
(SETGVHD) ☐ 1 - Yes ☐ 2 - No	*(SETDRGRX)* ☐ 1 - Yes ☐ 2 - No	*(SETCRTOX)* ☐ 1 - Yes ☐ 2 - No
Infection	**Other**	
(SETINFCT) ☐ 1 - Yes ☐ 2 - No	*(SETOTHER)* ☐ 1 - Yes ☐ 2 - No	

Specify other skin etiologies:*(GVHSKNSP)*

7. Skin biopsy for GVHD:*(GVHSKINB)*

   1 - Positive
   2 - Negative
   3 - Equivocal
   4 - Not Done

8. Upper GI abnormalities:*(GVHUPGIA)*

   0 - No Protracted Nausea and Vomiting
   1 - Persistent Nausea, Vomiting or Anorexia

9. Upper intestinal tract etiologies:

GVHD	Drug Reaction	Conditioning Regimen Toxicity
(UGIETGVH) ☐ 1 - Yes ☐ 2 - No	*(UGIETDRG)* ☐ 1 - Yes ☐ 2 - No	*(UGIETCON)* ☐ 1 - Yes ☐ 2 - No
TPN	**Infection**	**Other**
(UGIETTPN) ☐ 1 - Yes ☐ 2 - No	*(UGIETINF)* ☐ 1 - Yes ☐ 2 - No	*(UGIETOTH)* ☐ 1 - Yes ☐ 2 - No

Specify other upper intestinal tract etiologies:*(UGIETSPC)*

10. Upper intestinal tract biopsy for GVHD:*(UGIBIORS)*

1 - Positive
2 - Negative
3 - Equivocal
4 - Not Done

11. Lower GI abnormalities:*(GVHINTA)*

0 - No Diarrhea
1 - Diarrhea Less Than or Equal to 500 mL/day or <280 mL/m^2
2 - Diarrhea >500 but Less Than or Equal to 1000 mL/day or 280-555 mL/m^2
3 - Diarrhea >1000 but Less Than or Equal to 1500 mL/day or 556-833 mL/m^2
4 - Diarrhea >1500 mL/day or >833 mL/m^2
*Additional Options Listed Below

Use mL/day for adult patients and mL/m^2 for pediatric patients

12. Lower intestinal tract etiologies:

GVHD	Drug Reaction	Conditioning Regimen Toxicity
(LGIETGVH) ☐ 1 - Yes ☐ 2 - No	*(LGIETDRG)* ☐ 1 - Yes ☐ 2 - No	*(LGIETCON)* ☐ 1 - Yes ☐ 2 - No
TPN	**Infection**	**Other**
(LGIETTPN) ☐ 1 - Yes ☐ 2 - No	*(LGIETINF)* ☐ 1 - Yes ☐ 2 - No	*(LGIETOTH)* ☐ 1 - Yes ☐ 2 - No

Specify other lower intestinal tract etiologies:*(LGIETSPC)*

13. Lower intestinal tract biopsy for GVHD:*(LGIBIORS)*

1 - Positive
2 - Negative
3 - Equivocal
4 - Not Done

14. Liver abnormalities:*(GVHLIVRA)*

0 - Bilirubin <2.0 mg/dL
1 - Bilirubin 2.0-3.0 mg/dL
2 - Bilirubin 3.1-6.0 mg/dL
3 - Bilirubin 6.1-15.0 mg/dL
4 - Bilirubin >15.0 mg/dL

15. Liver etiologies:

GVHD	Drug Reaction	Conditioning Regimen Toxicity	TPN
(LIVETGVH) ☐ 1 - Yes ☐ 2 - No	*(LIVETDRG)* ☐ 1 - Yes ☐ 2 - No	*(LIVETCND)* ☐ 1 - Yes ☐ 2 - No	*(LIVETTPN)* ☐ 1 - Yes ☐ 2 - No
Infection	**VOD**	**Other**	
(LIVETINF) ☐ 1 - Yes ☐ 2 - No	*(LIVETVOD)* ☐ 1 - Yes ☐ 2 - No	*(LIVETOTH)* ☐ 1 - Yes ☐ 2 - No	

Specify other liver etiologies:*(GVHLIVRS)*

16. Liver biopsy for GVHD:*(GVHLIVRB)*

1 - Positive
2 - Negative
3 - Equivocal
4 - Not Done

17. Was any treatment of GVHD modified during this assessment period? ☐ 1 - Yes ☐ 2 - No
(GVHTHERP)

This only applies to TREATMENT for GVHD. If GVHD prophylaxis was the only modification during this assessment period, this question should be answered "2 - No".

18. If yes, specify agent name:*(GVHAGENT)*

1 - CSA
2 - FK506
3 - Topical Steroids
4 - Prednisone
5 - ATG
*Additional Options Listed Below

Specify other agent:*(GVHAGNSP)*

19. Indicate treatment modification:*(GVHTRMOD)*

1 - Started
2 - Stopped
4 - Tapered
5 - Increased

Comments:*(GVHCOMM)*

Additional Selection Options for GVH

Lower GI abnormalities:
5 - Severe Abdominal Pain with or without Ileus, or Stool with Frank Blood or Melena

If yes, specify agent name:
6 - MMF
7 - Daclizumab
8 - Methylprednisolone
9 - Other

Blood and Marrow Transplant Clinical Trials Network

Myeloablative Hematopoiesis Form (HEM)

Web Version: 1.0; 7.01; 10-16-15

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

1. Did the patient achieve ANC recovery ≥500/mm^3 on three consecutive days? *(ENGRFT1)* ☐ 1 - Yes ☐ 2 - No ☐ 3 - Previously Reported

2. Record neutrophil count and specimen collection dates:

Day 1:	*(ANCDAY1)*	*(xxxxx)* /mm^3	*(ANC1DT)*		*(mm/dd/yyyy)*
Day 2:	*(ANCDAY2)*	*(xxxxx)* /mm^3	*(ANC2DT)*		*(mm/dd/yyyy)*
Day 3:	*(ANCDAY3)*	*(xxxxx)* /mm^3	*(ANC3DT)*		*(mm/dd/yyyy)*

3. Patient randomized to receive: *(IFUNUM)*
   1 - One UCB
   2 - Two UCB
   3 - Single UCB assigned, however, site decided to give Double UCB
   4 - Double UCB assigned, however, site decided to give Single UCB

4. First CBU Bank ID: *(DONOR1ID)*

5. Second CBU Bank ID: *(DONOR2ID)*

Record Chimerism Assay Data for Marrow and/or Blood

Marrow

6. Was a chimerism performed on a marrow sample? *(MRWDONE)* ☐ 1 - Yes ☐ 2 - No
7. Date specimen collected: *(MRWDT2)* *(mm/dd/yyyy)*
8. Method of evaluation: *(MTHOD1)*
   1 - Standard Cytogenetics
   2 - Fluorescent In Situ Hybridization (FISH)
   3 - Restriction Fragment-Length Polymorphisms (RFLP)
   4 - Polymerase Chain Reaction (PCR) [VNTR, STR, microminisatellite]
   5 - HLA Serotyping
   *Additional Options Listed Below

   Specify other: *(MRWSPEC)*
9. Cell type: *(MRWCLTYP)* ☐ 1 - Unmanipulated ☐ 2 - Granulocytes
10. Marrow assay results: *(MRWASSAY)*
    1 - All Host Cells
    2 - All Donor Cells
    3 - Host and Donor
11. % Donor: *(PCNTDNR1)* *(xx)* %
12. Marrow assay results for two infusions: *(CB2MRWAS)*
    1 - All Host Cells
    2 - All CBU1 Cells
    3 - All CBU2 Cells
    4 - Host and CBU1 Cells Only
    5 - Host and CBU2 Cells Only
    *Additional Options Listed Below
13. % Host: *(MRWHOSTP)* *(xx)*
14. % CBU1: *(MRWCB1PC)* *(xx)*
15. % CBU2: *(MRWCB2PC)* *(xx)*

Blood

16. Was a chimerism performed on a blood sample? *(BLDDONE)* ☐ 1 - Yes ☐ 2 - No
17. Date specimen collected: *(BLDCHMDT)* *(mm/dd/yyyy)*

18. Method of evaluation:*(MTHOD2)*

1 - Standard Cytogenetics
2 - Fluorescent In Situ Hybridization (FISH)
3 - Restriction Fragment-Length Polymorphisms (RFLP)
4 - Polymerase Chain Reaction (PCR) [VNTR, STR, microminisatellite]
5 - HLA Serotyping
*Additional Options Listed Below

Specify other:*(BLDSPEC)*

19. Cell type:*(BLDCLTYP)* ☐ 1 - Unmanipulated ☐ 2 - Granulocytes

20. Blood assay results:*(BLDASSAY)*

1 - All Host Cells
2 - All Donor Cells
3 - Host and Donor

21. % Donor:*(PCNTDNR2)* *(xx)* %

22. Blood assay results for two infusions:*(CB2BLDAS)*

1-All Host Cells
2-All CBU1 Cells
3-All CBU2 Cells
4-Host and CBU1 Cells Only
5-Host and CBU2 Cells Only
*Additional Options Listed Below

23. % Host:*(BLDHOSTP)* *(xx)*

24. % CBU1:*(BLDCB1PC)* *(xx)*

25. % CBU2:*(BLDCB2PC)* *(xx)*

T Cell Chimerism

26. Was a chimerism performed on a T cell sample?*(TCLDONE)* ☐ 1 - Yes ☐ 2 - No

27. Type of sample:*(TCLSMPL)* ☐ 1 - Blood ☐ 2 - Marrow

28. Date specimen collected:*(TCLDATE)* *(mm/dd/yyyy)*

29. Method of evaluation:*(MTHOD3)*

1 - Standard Cytogenetics
2 - Fluorescent In Situ Hybridization (FISH)
3 - Restriction Fragment-Length Polymorphisms (RFLP)
4 - Polymerase Chain Reaction (PCR) [VNTR, STR, microminisatellite]
5 - HLA Serotyping
*Additional Options Listed Below

Specify other:*(TCLSPEC)*

30. T cell assay results:*(TCLASSAY)*

1 - All Host Cells
2 - All Donor Cells
3 - Host and Donor

31. % Donor:*(PCNTDNR3)* *(xx)* %

32. T cell assay results for two infusions:*(CB2TCHAS)*

1-All Host Cells
2-All CBU1 Cells
3-All CBU2 Cells
4-Host and CBU1 Cells Only
5-Host and CBU2 Cells Only
*Additional Options Listed Below

33. % Host:*(TCHHOSTP)* *(xx)*

34. % CBU1:*(TCHCB1PC)* *(xx)*

35. % CBU2:*(TCHCB2PC)* *(xx)*

36. Did the patient receive a stem cell re-infusion due to inadequate hematopoietic function?*(REINFUSE)* ☐ 1 - Yes ☐ 2 - No

37. Record date of infusion:*(INFUSEDT)* *(mm/dd/yyyy)*

Engraftment Syndrome

38. Did the patient have engraftment syndrome?*(ENGRFTSN)* ☐ 1 - Yes ☐ 2 - No

39. Date of onset:*(DTENGRFT)* *(mm/dd/yyyy)*

40. Did the patient have a skin rash?*(SKINRASH)* ☐ 1 - Yes ☐ 2 - No

41. If yes, what was the percent body surface area?*(BDYAREAR)* *(xxx)* %

42. Did the patient have a fever?*(ENGFEVER)* ☐ 1 - Yes ☐ 2 - No

43. Was the patient treated with corticosteroids?*(CORTSTER)* ☐ 1 - Yes ☐ 2 - No

Comments:*(HEMCOMM1)*

Additional Selection Options for HEM

Method of evaluation:
9 - Other, specify

Marrow assay results for two infusions:
6- CBU1 and CBU2 Cells Only
7- Host, CBU1, and CBU2 Cells

Blood and Marrow Transplant Clinical Trials Network

Infusion Form (IFU)

Web Version: 1.0; 6.02; 03-09-10

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

1. Patient is randomized to receive:*(IFUNUMB)*

1-One UCB
2-Two UCB
3-Single UCB assigned, however, site decided to give Double UCB
4-Double UCB assigned, however, site decided to give Single UCB

2. Date of CBU infusion:*(CBUINFDT)* *(mm/dd/yyyy)*
3. Patient's weight:*(CBUWEIGH)* *(xxx.x)* kg

Cord Blood Unit Infusion #1

4. First CBU Bank ID:*(CB1IDBNK)*

If the CBU bank ID is incorrect, please correct the CBU bank ID above

5. What order was this unit infused?*(CB1INORD)* ☐ 1 - First ☐ 2 - Second ☐ 3 - Not Infused
6. Date of collection of CBU:*(CB1CLDT)* *(mm/dd/yyyy)*
7. Pre-cryopreservation total nucleated cell count: *(CB1PRENU)* *(xx.x)* x 10^8 NC
8. Post-thaw total nucleated cell count:*(CB1POSNU)* *(xx.x)* x 10^8 NC
9. Pre-cryopreservation CD34+ cell count:*(CB1PRECD)* *(xx.x)* x 10^6 CD34+ cells
10. Post-thaw CD34+ cell count:*(CB1POSCD)* *(xx.x)* x 10^6 CD34+ cells
11. Pre-cryopreservation CD3+ cell count:*(CB1CD3PR)* *(xxx.x)* x 10^6 CD3+ cells
12. Post-thaw CD3+ cell count:*(CB1CD3PO)* *(xxx.x)* x 10^6 CD3+ cells
13. Was the post-thaw sterility test of the CBU positive? *(CB1STRTS)* ☐ 1 - Yes ☐ 2 - No

Cord Blood Unit Infusion #2

14. Second CBU Bank ID:*(CB2IDBNK)*

If the CBU bank ID is incorrect, please correct the CBU bank ID above

15. What order was this unit infused?*(CB2INORD)* ☐ 1 - First ☐ 2 - Second ☐ 3 - Not Infused
16. Date of collection of CBU:*(CB2CLDT)* *(mm/dd/yyyy)*
17. Pre-cryopreservation total nucleated cell count: *(CB2PRENU)* *(xx.x)* x 10^8 NC
18. Post-thaw total nucleated cell count:*(CB2POSNU)* *(xx.x)* x 10^8 NC
19. Pre-cryopreservation CD34+ cell count:*(CB2PRECD)* *(xx.x)* x 10^6 CD34+ cells
20. Post-thaw CD34+ cell count:*(CB2POSCD)* *(xx.x)* x 10^6 CD34+ cells
21. Pre-cryopreservation CD3+ cell count:*(CB2CD3PR)* *(xxx.x)* x 10^6 CD3+ cells
22. Post-thaw CD3+ cell count:*(CB2CD3PO)* *(xxx.x)* x 10^6 CD3+ cells
23. Was the post-thaw sterility test of the CBU positive? *(CB2STRTS)* ☐ 1 - Yes ☐ 2 - No

Toxicities Associated with Infusion

24. Were there any grade 3-5 toxicities assoicated with the infusion?*(CBUTOXGR)* ☐ 1 - Yes ☐ 2 - No

Record the highest grade of complication/toxicity that occurred within 24 hours of infusion.

25. Allergic reaction/hypersensitivity:*(CBUALRGY)*

0-Grades 0-2
3-Symptomatic Bronchospasm, with or without Urticaria; Parenteral Med(s) Indicated
4-Anaphylaxis
5-Death

26. Sinus bradycardia:*(CBUBRADY)*

0 - Grade 0-2
3 - Symptomatic and Requiring Treatment
4 - Life-Threatening (e.g. Arrhythmia Associate with CHF, Hypotension Syncope, Shock)
5 - Death

27. Sinus tachycardia:*(CBUTACHY)*

0 - Grade 0-2
3 - Symptomatic and Requiring Treatment of Underlying Cause
4 - Life-Threatening (e.g. Arrhythmia Associate with CHF, Hypotension Syncope, Shock)
5 - Death

28. Hypertension:*(CBUHYPER)*

0 - Grades 0-2
3 - Requiring More than One Drug or More Intensive Therapy than Previously
4 - Life-Threatening Consequences (e.g., Hypertensive Crisis)
5 - Death

29. Hypotension:*(CBUHYPOT)*

0 - Grades 0-2
3 - Sustained (>/= 24 hrs) Therapy, Resolves w/o Persisting Physiologic Consequences
4 - Shock (e.g., Acidemia; Impairment of Vital Organ Function)
5 - Death

30. Fever:*(CBUEVER)*

0 - Grade 0-2
3 - >40.0°C (>104.0°F) for <24 Hours
4 - >40.0°C (>104.0°F) for >24 Hours
5 - Death

31. Rigors, chills:*(CBUIGOR)*

0 - Grades 0-2
3 - Severe or Prolonged, not Responsive to Narcotics

32. Nausea:*(CBUNAUSE)*

0 - Grades 0-2
3 - No Significant Intake, Requiring IV Fluids
4 - Life-threatening Consequences
5 - Death

33. Vomiting:*(CBUVOMIT)*

0 - Grade 0-2
3 - >= 6 Episodes in 24 Hours Over Pre-Treatment; or Need for IV Fluids
4 - Req. Parenteral Nutrition; or Phys. Consequences Requiring Intensive Care; Hemodynamic Collapse
5 - Death

34. Infection, bacterium:*(CBUINFCT)*

0 - Grade 0-2
3 - Severe
4 - Life-Threatening
5 - Death

35. Dyspnea:*(CBUDYSPN)*

0 - Grades 0-2
3 - Dyspnea with Activities of Daily Living
4 - Dyspnea at Rest; Intubation or Ventilator Indicated
5 - Death

36. Hypoxia:*(CBUHYPOX)*

0 - Grades 0-2
3 - Decreased Oxygen Saturation at Rest; Continuous Oxygen Indicated
4 - Life-Threatening; Intubation or Ventilation Indicated
5 - Death

37. Hemoglobinuria:*(CBUHMOGL)*

0 - None
1 - Present

Comments:*(INFCOMNT)*

Blood and Marrow Transplant Clinical Trials Network

Infection Form (INF)

Web Version: 1.0; 4.01; 10-16-15

Segment *(PROTSEG)*:
Infection Site *(INFSITE)*:
Infection Start Date *(INFSTDT)*:

INFECTION I

1. Type of infection:*(INFTYP01)*
   - B - Bacteria
   - V - Viral
   - F - Fungal
   - P - Protozoal
   - O - Other

2. Organism I:*(ORGN01)*
   - B01 - Acinetobacter (baumanii, calcoaceticus, lwoffi, other species)
   - B02 - Agrobacterium radiobacter
   - B03 - Alcaligenes xylosoxidans
   - B04 - Anaerobic bacteria (NOS, except for Bacteroides, Clostridium)
   - B05 - Bacillus (cereus, other species)
   - *Additional Options Listed Below

   If other specify:*(INFSPEC1)*

3. Record the level of certainty of the fungal infection diagnosis:*(CERTNTY1)*
   - 1 - Proven Fungal Infection
   - 2 - Probable Fungal Infection
   - 3 - Possible Fungal Infection

4. Severity of infection:*(SVRTY01)*
   - 1 - Moderate
   - 2 - Severe
   - 3 - Life-Threatening/Fatal

INFECTION II

5. Type of infection:*(INFTYP02)*
   - B - Bacteria
   - V - Viral
   - F - Fungal
   - P - Protozoal
   - O - Other

6. Organism II:*(ORGN02)*
   - B01 - Acinetobacter (baumanii, calcoaceticus, lwoffi, other species)
   - B02 - Agrobacterium radiobacter
   - B03 - Alcaligenes xylosoxidans
   - B04 - Anaerobic bacteria (NOS, except for Bacteroides, Clostridium)
   - B05 - Bacillus (cereus, other species)
   - *Additional Options Listed Below

   If other specify:*(INFSPEC2)*

7. Record the level of certainty of the fungal infection diagnosis:*(CERTNTY2)*
   - 1 - Proven Fungal Infection
   - 2 - Probable Fungal Infection
   - 3 - Possible Fungal Infection

8. Severity of infection:*(SVRTY02)*
   - 1 - Moderate
   - 2 - Severe
   - 3 - Life-Threatening/Fatal

INFECTION III

9. Type of infection:*(INFTYP03)*
   - B - Bacteria
   - V - Viral
   - F - Fungal
   - P - Protozoal
   - O - Other

10. Organism III:*(ORGN03)*

B01 - Acinetobacter (baumanii, calcoaceticus, lwoffi, other species)
B02 - Agrobacterium radiobacter
B03 - Alcaligenes xylosoxidans
B04 - Anaerobic bacteria (NOS, except for Bacteroides, Clostridium)
B05 - Bacillus (cereus, other species)
*Additional Options Listed Below

If other specify:*(INFSPEC3)*

11. Record the level of certainty of the fungal infection diagnosis:*(CERTNTY3)*

1 - Proven Fungal Infection
2 - Probable Fungal Infection
3 - Possible Fungal Infection

12. Severity of infection:*(SVRTY03)*

1 - Moderate
2 - Severe
3 - Life-Threatening/Fatal

13. Was an agent(s) administered to treat the infection(s)?*(TRTINF)* ☐ 1 - Yes ☐ 2 - No

Provide agent(s) administered for this infectious period:

14. 1st agent:*(AGENT1)*

abacavir (Ziagen)
acyclovir (Zovirax)
albendazole (Albenza)
amantadine (Symmetrel, Symadine)
amikacin (Amikin)
*Additional Options Listed Below

If other specify:*(AGTSPEC1)*

15. 2nd agent:*(AGENT2)*

abacavir (Ziagen)
acyclovir (Zovirax)
albendazole (Albenza)
amantadine (Symmetrel, Symadine)
amikacin (Amikin)
*Additional Options Listed Below

If other specify:*(AGTSPEC2)*

16. 3rd agent:*(AGENT3)*

abacavir (Ziagen)
acyclovir (Zovirax)
albendazole (Albenza)
amantadine (Symmetrel, Symadine)
amikacin (Amikin)
*Additional Options Listed Below

If other specify:*(AGTSPEC3)*

17. Were additional agents administered for this infectious period?*(ADDAGENT)* ☐ 1 - Yes ☐ 2 - No

If yes, specify additional agents administered:*(INFSPEC4)*

Comments:*(INFCOM)*

Additional Selection Options for INF

Infection Site *(INFSITE)* (key field):
01 - Blood/Buffy Coat
02 - Disseminated - Generalized, Isolated at 2 or More Distinct Sites
03 - Brain
04 - Spinal Cord
05 - Meninges and CSF
06 - Central Nervous System Unspecified
07 - Lips
08 - Tongue, Oral Cavity, and Oro-Pharynx
09 - Esophagus
10 - Stomach
11 - Gallbladder and Biliary Tree (Not Hepatitis), Pancreas
12 - Small Intestine
13 - Large Intestine
14 - Feces/Stool
15 - Peritoneum
16 - Liver
17 - Gastrointestinal Tract Unspecified
18 - Upper Airway and Nasopharynx
19 - Larynx
20 - Lower Respiratory Tract (Lung)
21 - Pleural Cavity, Pleural Fluid
22 - Sinuses
23 - Respiratory Tract Unspecified
24 - Kidneys, Renal Pelvis, Ureters and Bladder
25 - Prostate
26 - Testes
27 - Fallopian Tubes, Uterus, Cervix
28 - Vagina
29 - Genito-Urinary Tract Unspecified
30 - Genital Area
31 - Rash, Pustules, or Abscesses Not Typical of Any of the Above
32 - Skin Unspecified
33 - Woundsite
34 - Catheter Tip
35 - Eyes
36 - Ears
37 - Joints
38 - Bone Marrow
39 - Bone Cortex (Osteomyelitis)
40 - Muscle (Excluding Cardiac)
41 - Cardiac (Endocardium, Myocardium, Pericardium)
42 - Lymph Nodes
43 - Spleen
99 - Other Unspecified

Organism I:
B06 - Bacteroides (gracillis, uniformis, vulgaris, other species)
B07 - Borrelia (Lyme disease)
B08 - Branhamelia or Moraxella catarrhalis (other species)
B09 - Campylobacter (all species)
B11 - Chlamydia
B12 - Citrobacter (freundii, other species)
B13 - Clostridium (all species except difficile)
B14 - Clostridium difficile
B15 - Corynebacterium (all non-diptheria species)
B16 - Coxiella
B17 - Enterobacter
B18 - Enterococcus (all species)
B19 - Escherichia (also E. coli)
B20 - Flavimonas oryzihabitans
B21 - Flavobacterium
B22 - Fusobacterium nucleatum
B23 - Gram Negative Diplococci (NOS)
B24 - Gram Negative Rod (NOS)
B25 - Gram Positive Cocci (NOS)
B26 - Gram Positive Rod (NOS)
B27 - Haemophilus (all species including influenzae)
B28 - Helicobacter pylori
B29 - Klebsiella
B30 - Lactobacillus (bulgaricus, acidophilus, other species)
B31 - Legionella
B32 - Leptospira
B33 - Leptotrichia buccalis
B34 - Leuconostoc (all species)
B35 - Listeria
B36 - Methylobacterium
B37 - Micrococcus (NOS)
B38 - Mycobacteria (avium, bovium, haemophilum, intercellulare)
B39 - Mycoplasma
B40 - Neisseria (gonorrhoea, meningitidis, other species)
B41 - Nocardia
B42 - Pharyngeal/Respiratory Flora
B43 - Propionibacterium (acnes, avidum,

granulosum, other species)
B44 - Pseudomonas (all species except
cepacia and maltophilia)
B45 - Pseudomonas or Burkholderia cepacia
B46 - Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia
B47 - Rhodococcus
B48 - Rickettsia
B49 - Salmonella (all species)
B50 - Serratia marcescens
B51 - Shigella
B52 - Staphylococcus (coag -)
B53 - Staphylococcus (coag +)
B54 - Staphylococcus (NOS)
B55 - Stomatococcus mucilaginosis
B56 - Streptococcus (all species except Enterococcus)
B57 - Treponema (syphilis)
B58 - Tuberculosis (NOS, AFB, acid fast bacillus, Koch bacillus)
B59 - Typical Tuberculosis (TB, Tuberculosis)
B60 - Vibrio (all species)
B99 - Other Bacteria
V01 - Herpes Simplex (HSV1, HSV2)
V02 - Herpes Zoster (Chicken pox, Varicella)
V03 - Cytomegalovirus (CMV)
V04 - Adenovirus
V05 - Enterovirus (Coxsackie, Echo, Polio)
V06 - Hepatitis A (HAV)
V07 - Hepatitis B (HBV, Australian antigen)
V08 - Hepatitis C (includes non-A and non-B, HCV)
V09 - HIV-1, HITLV-III
V10 - Influenza (Flu)
V11 - Measles (Rubeola)
V12 - Mumps
V13 - Papovavirus
V14 - Respiratory Syncytial virus (RSV)
V15 - Rubella (German Measles)
V16 - Parainfluenza
V17 - HHV-6 (Human Herpes Virus)
V18 - Epstein-Barr Virus (EBV)
V19 - Polyomavirus
V20 - Rotavirus
V21 - Rhinovirus (Common Cold)
V22 - Other Viral
P1 - Pneumoncystis (PCP)
P2 - Toxoplasma
P3 - Giardia
P4 - Cryptosporidium
P5 - Amebiasis
P6 - Echinococalcyst
P7 - Trichomonas (either vaginal or gingivitis)
P8 - Other Protozoal (Parasite)
O1 - Mycobacterium Tuberculosis
O2 - Other Mycobacterium
O3 - Mycoplasma
O4 - Other Organism
F01 - Candida Albicans
F02 - Candida Krusei
F03 - Candida Parasilosis
F04 - Candida Tropicalis
F05 - Torulopsis Galbrata (a subspecies of Candida)
F06 - Candida (NOS)
F07 - Asperguillus Flavus
F08 - Asperguillus Fumigatus
F09 - Asperguillus Niger
F10 - Asperguillus (NOS)
F11 - Cryptococcus Species
F12 - Fusarium Species
F13 - Mucormycosis (Zygomycetes, Rhizopus)
F14 - Yeast (NOS)
F15 - Other Fungus

1st agent:
amoxicillin / clavulanate (Augmentin)
amphotericin b (Abelcet, Amphotec, Fungizone)
ampicillin (Omnipen, Polycillin)
ampicillin / sulbactam (Unasyn)
amprenavir (Agenerase)
atovaquone (Meprone)
azithromycin (Zithromax, Z-Pack)
cefaclor (Ceclor)
cefadroxil (Duricef, Ultracef)
cefazolin (Ancef, Kefzol)
cefdinir (Omnicef)
cefepime (Maxipime)
cefixime (Suprax)
cefoperazone (Cefobid)
cefotaxime (Claforan)
cefotetan (Cefotan)

cefoxitin (Mefoxin)
cefpodoxime (Vantin)
cefprozil (Cefzil)
ceftazidime (Fortaz, Tazicef)
ceftriaxone (Rocephin)
cefuroxime (Ceftin, Kefurox, Zinacef)
cephalexin (Keflet, Keflex, Keftab)
chloramphenicol (Chloromycetin)
cidofovir (Vistide)
ciprofloxacin (Cipro)
clarithromycin (Biaxin)
clindamycin (Cleocin)
clotrimazole (Mycelex, Lotrimin)
clotrimoxazole / betamethasone (Lotrisone)
co-trimoxazole (Bactrim, Septra, Sulfamethoprim)
dapsone (DDS)
dicloxacillin (Dycill, Dynapen, Pathocil)
didanosine (Videx, ddI)
doxycycline (Vibramycin)
efavirenz (Sustiva)
erythromycin (Ery-Tab, Ilosone, Pediamycin)
erythromycin ethyl/sulfisoxazole (Pediazole)
erythromycin topical (Akne-mycin, Eryderm)
ethambutol (Myambutol)
famciclovir (Famvir)
fluconazole (Diflucan)
flucytosine (Ancobon)
foscarnet (Foscavir)
ganciclovir (Cytovene)
gatifloxacin (Tequin)
gentamicin (Garamycin, Gentacidin)
grepafloxacin (Raxar)
hepatitis a vaccine (Havrix, Vaqta)
hepatitis b vaccine (Recombivax HB, Engerix-B)
hepatitis c vaccine
imipenem / cilastatin (Primaxin)
imiquimod (Aldara)
indinavir (Crixivan)
interferon alfacon-1 (Infergen)
interferon beta-1a (Avonex)
interferon beta-1b (Betaseron)
isoniazid (INH, Lanizid, Nydrazid)
itraconazole (Sporonox)
ivermectin (Stromectol)
kanamycin (Kantrex)
ketoconazole (Nizoral)
lamivudine (Epivir, 3TC)
levofloxacin (Levaquin)
linezolid (Zyvox)
lopinavir/ritonavir (Kaletra)
mefloquine (Larium)
meropenem (Merrem I.V.)
metronidazole (Flagyl, Protostat)
minocycline (Arestin)
moxifloxacin hydrochloride (Avelox)
mupirocin (Bactroban)
nafcillin (Nallpen, Unipen)
nelfinavir (Viracept)
neomycin (Mycifradin, Myciguent)
neomycin / polymxin / hydrocortisone (Cortisporin)
nevirapine (Viramune)
nitrofurantoin (Macrobid)
nystatin (Mycostatin)
oseltamivir (Tamiflu)
oxacillin (Bactocill)
palivizumab (Synagis)
penicillin g (Bicillin)
penicillin vk (V-Cillin K, Veetids)
pentamidine (Pentam 300)
piperacillin (Pipracil)
piperacillin/tazobactam (Zosyn)
podofilox (Condylox)
polymyxin (Ak-Spore H.C., Cortisporin Ophthalmic Suspension)
PPD skin test (Mantoux Test, Tine Test)
pyrazinamide (Rifater)
pyrimethamine (Daraprim)
quinidine gluconate (Duraquin, Cardioqiuin)
quinupristin/dalfopristin (Synercid)
respiratory syncytial immune globulin (Respigam)
ribavirin (Virazole)
rifampin (Rifadin, Rimactane)
rifampin/isoniazid (Rifamate, Rimactane/INH)
rifampin/isoniazid/pyrazinamide (Rifater)
rimantadine (Flumadine)
ritonavir (Norvir)
saquinavir mesylate (Fortovase, Invirase)
stavudine (d4T, Zerit)

streptomycin (Streptomycin sulfate)
sulfamethoxazole / trimethoprim (Bactrim)
terbinafine (Lamisil)
terconazole (Terazol)
tetracycline (Achromycin)
ticarcillin / clavulanate (Ticar, Timentin)
tobramycin (Nebcin, Tobrex, TobraDex)
trimethoprim / sulfamethoxazole (Bactrim, Septra, Co-trimoxazole)
valacyclovir (Valtrex)
valganciclovir (Valcyte)
vancomycin (Vancocin)
zidovudine (AZT, Retrovir)
other

Blood and Marrow Transplant Clinical Trials Network

Immune Reconstitution Form - 0501 (IRF)

Web Version: 1.0; 2.03; 10-16-15

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

1. Were the immune reconstitution tests at one year post-transplant abnormal? *(YR1ABTST)* ☐ 1 - Yes ☐ 2 - No
2. Has the patient developed chronic GVHD in the last year?*(CGVHDDEV)* ☐ 1 - Yes ☐ 2 - No

If both questions are answered no, immune reconstitution assays are not required two years post-transplant.

Immunizations

3. Record type of immunization administered:*(TYPEIMUZ)*

1 - Tetanus
2 - Tetanus and Diphtheria
3 - DTaP
9 - Other, Specify

Specify other immunization:*(IRFTYOTH)*

4. Date and time of immunization:*(IRFIMZDT)* *(mm/dd/yyyy)* *(IRFIMZTM)* *(hh:mm)*

Flow Cytometry

5. Date flow cytometry was performed:*(DTFCIRF)* *(mm/dd/yyyy)*
6. White blood cell count:*(WBCIRF)* *(xxxxx)* x 10^9/L
7. Percent lymphocyte of CD45+ cells:*(LMYPHIRF)* *(xxx)* %
8. CD3:*(CD3IRF)* *(xxxxx)* cells/uL
9. CD4:*(CD4IRF)* *(xxxxx)* cells/uL
10. CD8:*(CD8IRF)* *(xxxxx)* cells/uL
11. CD19+:*(CD19IRF)* *(xxxxx)* cells/uL
12. CD56+/CD16+:*(CD56IRF)* *(xxxxx)* cells/uL

Quantitative Immunoglobulins

13. Date quantitative immunoglobulins assay was performed:*(DTQIIRF)* *(mm/dd/yyyy)*

	Value	Lower Limit of Normal	Upper Limit of Normal
14. IgA:	*(IGAIRF)* *(xxx)* mg/dL	*(IGALLNRF)* *(xxx)* mg/dL	*(IGAULNRF)* *(xxx)* mg/dL
15. IgG:	*(IGGIRF)* *(xxxx)* mg/dL	*(IGGLLNRF)* *(xxxx)* mg/dL	*(IGGULNRF)* *(xxxx)* mg/dL
16. IgM:	*(IGMIRF)* *(xxxx)* mg/dL	*(IGMLLNRF)* *(xxxx)* mg/dL	*(IGMULNRF)* *(xxxx)* mg/dL
17. IgE:	*(IGEIRF)* *(xxx)* IU/mL	*(IGELLNRF)* *(xxx)* IU/mL	*(IGEULNRF)* *(xxx)* IU/mL

18. Were immunoglobulin products administered during this assessment period? *(IRFPADMN)* ☐ 1 - Yes ☐ 2 - No
19. Record date of last administration:*(IRFADMDT)* *(mm/dd/yyyy)*

Comments:*(COMMIRF)*



Blood and Marrow Transplant Clinical Trials Network

Relapse Form (RLP)

Web Version: 1.0; 4.00; 10-16-15

Disease *(RELAPSDX)*:

Acute Leukemia

1. Have leukemia blast cells reappeared in the peripheral blood?*(RLALLBPB)* ☐ 1 - Yes ☐ 2 - No
   2. If yes, specify date of reappearance:*(RLBPBDT)* _____ *(mm/dd/yyyy)*
3. Have new dysplastic changes appeared within the bone marrow?*(RLALLDYS)* ☐ 1 - Yes ☐ 2 - No
   4. If yes, specify date changes appeared:*(RLDYSDT)* _____ *(mm/dd/yyyy)*
5. Were leukemic blasts documented in the bone marrow after transplantation? *(RLALLBL1)* ☐ 1 - Yes ☐ 2 - No

   If yes, indicate the following:
   6. Date blasts documented:*(RLALLDT1)* _____ *(mm/dd/yyyy)*
   7. % Leukemic blasts documented:*(RLALLPR1)* _____ *(xxx)* %
   8. Were these blasts attributable to another cause (e.g. bone marrow regeneration)?*(RLALLBAT)* ☐ 1 - Yes ☐ 2 - No
      9. If yes, specify the other cause:*(RLALLBA0)* _____
   10. Were leukemic blasts documented in the bone marrow after transplantation by a second biopsy?*(RLALLBL2)* ☐ 1 - Yes ☐ 2 - No

   If yes, indicate the following:
   11. Date blasts documented in second biopsy:*(RLALLDT2)* _____ *(mm/dd/yyyy)*
   12. % Leukemic blasts documented in second biopsy:*(RLALLPR2)* _____ *(xxx)* %
13. Was leukemia detected at an extramedullary site?*(RLALEXTR)* ☐ 1 - Yes ☐ 2 - No
   14. If yes, indicate date disease first detected:*(RLALEXDT)* _____ *(mm/dd/yyyy)*
15. Were leukemic cells detected in the cerebrospinal fluid?*(RLALCSF)* ☐ 1 - Yes ☐ 2 - No
   16. If yes, indicate date cells first detected:*(RLALCSDT)* _____ *(mm/dd/yyyy)*

Chronic Myelogenous Leukemia (CML)

Hematologic Relapse

17. Have immature hematopoietic cells been documented in the peripheral blood? *(RLCMIMMC)* ☐ 1 - Yes ☐ 2 - No
   18. If yes, indicate date cells first documented:*(RLCMIMDT)* _____ *(mm/dd/yyyy)*
19. Has myeloid hyperplasia been documented in the bone marrow in the presence of cytogenetics relapse?*(RLCMMYHY)* ☐ 1 - Yes ☐ 2 - No
   20. If yes, indicate date myeloid hyperplasia first documented:*(RLCMMYDT)* _____ *(mm/dd/yyyy)*

Cytogenetic Relapse

21. Have metaphases exhibiting 9;22 translocation been detected?*(RLCMCYT1)* ☐ 1 - Yes ☐ 2 - No

   If yes, indicate the following:
   22. Date of analysis:*(RLCMCYD1)* _____ *(mm/dd/yyyy)*
   23. Number of metaphases analyzed:*(RLCMNAN1)* _____ *(xxx)*
   24. Number of metaphases exhibiting 9;22 translocation detected:*(RLCMNTR1)* _____ *(xxx)*
   25. Have metaphases exhibiting 9;22 translocation been detected on a second analysis?*(RLCMCYT2)* ☐ 1 - Yes ☐ 2 - No

   If yes, indicate the following:
   26. Date of second analysis:*(RLCMCYD2)* _____ *(mm/dd/yyyy)*
   27. Number of metaphases analyzed on second analysis:*(RLCMNAN2)* _____ *(xxx)*
   28. Number of metaphases exhibiting 9;22 translocation detected on second analysis:*(RLCMNTR2)* _____ *(xxx)*

Myelodysplastic (MDS) and Myeloproliferative Syndromes (includes CMML, AMM or Idiopathic Myelofibrosis, and JMML)

29. Have pre-transplant morphologic abnormalities reappeared in a bone marrow specimen?*(RLMDMRA)* ☐ 1 - Yes ☐ 2 - No

   If yes, indicate the following:

30. Date specimen obtained:*(RLMDMAD1)* *(mm/dd/yyyy)*

31. Have the abnormalities reappeared on a second bone marrow specimen? *(RLMD2MRA)* ☐ 1 - Yes ☐ 2 - No

32. If yes, indicate date second specimen obtained:*(RLMDMAD2)* *(mm/dd/yyyy)*

33. Have pre-transplant cytogenetic abnormalities reappeared?*(RLMDCY1)* ☐ 1 - Yes ☐ 2 - No

If yes, indicate the following:

34. Date of cytogenetic analysis:*(RLMDCYD1)* *(mm/dd/yyyy)*

35. Number of metaphases analyzed:*(RLMDCYA1)* *(xxx)*

36. Number of metaphases exhibiting pre-transplant cytogenetic abnormalities: *(RLMDCYN1)* *(xxx)*

37. Have pre-transplant cytogenetic abnormalities reappeared on a second analysis?*(RLMDCY2)* ☐ 1 - Yes ☐ 2 - No

38. Date of second cytogenetic analysis:*(RLMDCYD2)* *(mm/dd/yyyy)*

39. Number of metaphases analyzed on second analysis:*(RLMDCYA2)* *(xxx)*

40. Number of metaphases exhibiting pre-transplant cytogenetic abnormalities on second analysis:*(RLMDCYN2)* *(xxx)*

41. Has specific therapy, such as infusion of donor lymphocytes, use of interferon, or second transplant, been initiated for relapse reversal?*(RLRLPREV)* ☐ 1 - Yes ☐ 2 - No

42. If yes, specify date of initiation of therapy:*(RLREVDT)* *(mm/dd/yyyy)*

Comments:*(RLCOMM)*

Additional Selection Options for RLP

Disease *(RELAPSDX)* (key field):
1 - Acute Myelogenous Leukemia
2 - Acute Lymphoblastic Leukemia
3 - Chronic Myelogenous Leukemia
4 - Myelodysplastic Syndrome
5 - Chronic Myelomonocytic Leukemia
6 - Agnogenic Myeloid Metaplasia with Myelofibrosis
7 - Juvenile Myelomonocytic Leukemia

Blood and Marrow Transplant Clinical Trials Network

Secondary Graft Failure Form (SGF)

Web Version: 1.0; 3.02; 10-16-15

Segment *(PROTSEG)*:

1. Was there a decline in neutrophil counts to <500/mm^3 for three consecutive measurements on different days after initial neutrophil engraftment?*(DECANC)* ☐ 1 - Yes ☐ 2 - No

2. Record the first three consecutive neutrophil counts and specimen collection dates:

Day 1:	*(ANC1SGF)*		*(xxx)* /mm^3	*(ANC1SGDT)*	*(mm/dd/yyyy)*
Day 2:	*(ANC2SGF)*		*(xxx)* /mm^3	*(ANC2SGDT)*	*(mm/dd/yyyy)*
Day 3:	*(ANC3SGF)*		*(xxx)* /mm^3	*(ANC3SGDT)*	*(mm/dd/yyyy)*

3. Was growth factor administered following the decline in neutrophil counts? *(GFGIVEN)* ☐ 1 - Yes ☐ 2 - No

4. Did the neutrophil count respond to growth factor therapy?*(RSPNDGF)* ☐ 1 - Yes ☐ 2 - No

Comments:*(SGFCOMM)*

Blood and Marrow Transplant Clinical Trials Network

Sample Results Form - 0501 (SRF)

Web Version: 1.0; 6.00; 10-16-15

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

Immune Reconstitution Lab Results:

Titers	Is the value below the threshold of detection?	Value	Date Test Performed			
1. Tetanus Titer:	*(TETITTHR)* ☐ 1 - Yes ☐ 2 - No	*(TETITCB)* *(xx.xx)* IU/mL	*(TETITDT)* *(mm/dd/yyyy)*			
2. PRP Titer:	*(PRPTITTH)* ☐ 1 - Yes ☐ 2 - No	*(PRPTITCB)* *(xx.xx)* mcg/mL	*(PRPTITDT)* *(mm/dd/yyyy)*			
TREC						
3. CD8+ TREC:	*(CD8THRES)* ☐ 1 - Yes ☐ 2 - No	*(CD8TREC)* *(xxxxx)* TREC/10e5 CD8+ Tcells	*(CD8TRCDT)* *(mm/dd/yyyy)*			
4. CD4+ TREC:	*(CD4THRES)* ☐ 1 - Yes ☐ 2 - No	*(CD4TREC)* *(xxxxx)* TREC/10e5 CD4+ Tcells	*(CD4TRCDT)* *(mm/dd/yyyy)*			
Proliferation	**Is the first value below the threshold of detection?**	**Value**	**Is the second value below the threshold of detection?**	**Value**	**Date Test Performed**	
5. CMV-specific proliferation:	*(CMVTHRES)* ☐ 1 - Yes ☐ 2 - No	*(CMVPROCF)* 1st *(xxxxxx)* CPM	*(CMV2THR)* ☐ 1 - Yes ☐ 2 - No	*(CMVPROCS)* 2nd *(xxxxxx)* CPM	*(CMVPRODT)* *(mm/dd/yyyy)*	
6. HSV-specific proliferation:	*(HSVTHRES)* ☐ 1 - Yes ☐ 2 - No	*(HSVPROCF)* 1st *(xxxxxx)* CPM	*(HSV2THR)* ☐ 1 - Yes ☐ 2 - No	*(HSVPROCS)* 2nd *(xxxxxx)* CPM	*(HSVPRODT)* *(mm/dd/yyyy)*	
7. VZV-specific proliferation:	*(VZVTHRES)* ☐ 1 - Yes ☐ 2 - No	*(VZVPROCF)* 1st *(xxxxxx)* CPM	*(VZV2THR)* ☐ 1 - Yes ☐ 2 - No	*(VZVPROCS)* 2nd *(xxxxxx)* CPM	*(VZVPRODT)* *(mm/dd/yyyy)*	
8. Tetanus-specific profliferation:	*(TETTHRES)* ☐ 1 - Yes ☐ 2 - No	*(TETPROCF)* 1st *(xxxxxx)* CPM	*(TE2PRTHR)* ☐ 1 - Yes ☐ 2 - No	*(TETPROCS)* 2nd *(xxxxxx)* CPM	*(TETPRODT)* *(mm/dd/yyyy)*	
9. Control:	*(PROTHRES)* ☐ 1 - Yes ☐ 2 - No	*(PROCONCF)* 1st *(xxxxxx)* CPM	*(PRO2THR)* ☐ 1 - Yes ☐ 2 - No	*(PROCONCS)* 2nd *(xxxxxx)* CPM	*(PROCONDT)* *(mm/dd/yyyy)*	
Cytokine Secretion						
10. CMV-specific IL-2:	*(CMVIL2TH)* ☐ 1 - Yes ☐ 2 - No	*(CMVIL2CF)* 1st *(xxxx)* pg/mL	*(CMV2IL2T)* ☐ 1 - Yes ☐ 2 - No	*(CMVIL2CS)* 2nd *(xxxx)* pg/mL	*(CMVIL2DT)* *(mm/dd/yyyy)*	
11. CMV-specific IL-4:	*(CMVIL4TH)* ☐ 1 - Yes ☐ 2 - No	*(CMVIL4CF)* 1st *(xxxx)* pg/mL	*(CMV2IL4T)* ☐ 1 - Yes ☐ 2 - No	*(CMVIL4CS)* 2nd *(xxxx)* pg/mL	*(CMVIL4DT)* *(mm/dd/yyyy)*	
12. CMV-specific IL-10:	*(CMVI10TH)* ☐ 1 - Yes ☐ 2 - No	*(CMVIL10F)* 1st *(xxxx)* pg/mL	*(CMV2I10T)* ☐ 1 - Yes ☐ 2 - No	*(CMVIL10S)* 2nd *(xxxx)* pg/mL	*(CMVI10DT)* *(mm/dd/yyyy)*	
13. CMV-specific IFNg:	*(CMVIFNTH)* ☐ 1 - Yes ☐ 2 - No	*(CMVIFNGF)* 1st *(xxxx)* pg/mL	*(CMV2IFTH)* ☐ 1 - Yes ☐ 2 - No	*(CMVIFNGS)* 2nd *(xxxx)* pg/mL	*(CMVIFNDT)* *(mm/dd/yyyy)*	

14. CMV-specific TNFa:	*(CMVTNFTH)* ☐ 1 - Yes ☐ 2 - No	*(CMVTNFAF)* 1st *(xxxx)* pg/mL	*(CMV2TNTH)* ☐ 1 - Yes ☐ 2 - No	*(CMVTNFAS)* 2nd *(xxxx)* pg/mL	*(CMVTNFDT)* *(mm/dd /yyyy)*
15. HSV-specific IL-2:	*(HSVIL2TH)* ☐ 1 - Yes ☐ 2 - No	*(HSVIL2CF)* 1st *(xxxx)* pg/mL	*(HSV2IL2T)* ☐ 1 - Yes ☐ 2 - No	*(HSVIL2CS)* 2nd *(xxxx)* pg/mL	*(HSVIL2DT)* *(mm/dd /yyyy)*
16. HSV-specific IL-4:	*(HSVIL4TH)* ☐ 1 - Yes ☐ 2 - No	*(HSVIL4CF)* 1st *(xxxx)* pg/mL	*(HSV2IL4T)* ☐ 1 - Yes ☐ 2 - No	*(HSVIL4CS)* 2nd *(xxxx)* pg/mL	*(HSVIL4DT)* *(mm/dd /yyyy)*
17. HSV-specific IL-10:	*(HSVI10TH)* ☐ 1 - Yes ☐ 2 - No	*(HSVIL10F)* 1st *(xxxx)* pg/mL	*(HSV2I10T)* ☐ 1 - Yes ☐ 2 - No	*(HSVIL10S)* 2nd *(xxxx)* pg/mL	*(HSVI10DT)* *(mm/dd /yyyy)*
18. HSV-specific IFNg:	*(HSVIFNTH)* ☐ 1 - Yes ☐ 2 - No	*(HSVIFNGF)* 1st *(xxxx)* pg/mL	*(HSV2IFNT)* ☐ 1 - Yes ☐ 2 - No	*(HSVIFNGS)* 2nd *(xxxx)* pg/mL	*(HSVIFNDT)* *(mm/dd /yyyy)*
19. HSV-specific TNFa:	*(HSVTNFTH)* ☐ 1 - Yes ☐ 2 - No	*(HSVTNFAF)* 1st *(xxxx)* pg/mL	*(HSV2TNFT)* ☐ 1 - Yes ☐ 2 - No	*(HSVTNFAS)* 2nd *(xxxx)* pg/mL	*(HSVTNFDT)* *(mm/dd /yyyy)*
20. VZV-specific IL-2:	*(VZVIL2TH)* ☐ 1 - Yes ☐ 2 - No	*(VZVIL2CF)* 1st *(xxxx)* pg/mL	*(VZV2IL2T)* ☐ 1 - Yes ☐ 2 - No	*(VZVIL2CS)* 2nd *(xxxx)* pg/mL	*(VZVIL2DT)* *(mm/dd /yyyy)*
21. VZV-specific IL-4:	*(VZVIL4TH)* ☐ 1 - Yes ☐ 2 - No	*(VZVIL4CF)* 1st *(xxxx)* pg/mL	*(VZV2IL4T)* ☐ 1 - Yes ☐ 2 - No	*(VZVIL4CS)* 2nd *(xxxx)* pg/mL	*(VZVIL4DT)* *(mm/dd /yyyy)*
22. VZV-specific IL-10:	*(VZVI10TH)* ☐ 1 - Yes ☐ 2 - No	*(VZVIL10F)* 1st *(xxxx)* pg/mL	*(VZV2I10T)* ☐ 1 - Yes ☐ 2 - No	*(VZVIL10S)* 2nd *(xxxx)* pg/mL	*(VZVI10DT)* *(mm/dd /yyyy)*
23. VZV-specific IFNg:	*(VZVIFNTH)* ☐ 1 - Yes ☐ 2 - No	*(VZVIFNGF)* 1st *(xxxx)* pg/mL	*(VZV2IFNT)* ☐ 1 - Yes ☐ 2 - No	*(VZVIFNGS)* 2nd *(xxxx)* pg/mL	*(VZVIFNDT)* *(mm/dd /yyyy)*
24. VZV-specific TNFa:	*(VZVTNFTH)* ☐ 1 - Yes ☐ 2 - No	*(VZVTNFAF)* 1st *(xxxx)* pg/mL	*(VZV2TNFT)* ☐ 1 - Yes ☐ 2 - No	*(VZVTNFAS)* 2nd *(xxxx)* pg/mL	*(VZVTNFDT)* *(mm/dd /yyyy)*
25. Tetanus-specific IL-2:	*(TETIL2TH)* ☐ 1 - Yes ☐ 2 - No	*(TETIL2CF)* 1st *(xxxx)* pg/mL	*(TET2IL2T)* ☐ 1 - Yes ☐ 2 - No	*(TETIL2CS)* 2nd *(xxxx)* pg/mL	*(TETIL2DT)* *(mm/dd /yyyy)*
26. Tetanus-specific IL-4:	*(TETIL4TH)* ☐ 1 - Yes ☐ 2 - No	*(TETIL4CF)* 1st *(xxxx)* pg/mL	*(TET2IL4T)* ☐ 1 - Yes ☐ 2 - No	*(TETIL4CS)* 2nd *(xxxx)* pg/mL	*(TETIL4DT)* *(mm/dd /yyyy)*
27. Tetanus-specific IL-10:	*(TETI10TH)* ☐ 1 - Yes ☐ 2 - No	*(TETIL10F)* 1st *(xxxx)* pg/mL	*(TET2I10T)* ☐ 1 - Yes ☐ 2 - No	*(TETIL10S)* 2nd *(xxxx)* pg/mL	*(TETI10DT)* *(mm/dd /yyyy)*
28. Tetanus-specific IFNg:	*(TETIFNTH)* ☐ 1 - Yes ☐ 2 - No	*(TETIFNGF)* 1st *(xxxx)* pg/mL	*(TET2IFNT)* ☐ 1 - Yes ☐ 2 - No	*(TETIFNGS)* 2nd *(xxxx)* pg/mL	*(TETIFNDT)* *(mm/dd /yyyy)*
29. Tetanus-specific TNFa:	*(TETTNFTH)* ☐ 1 - Yes ☐ 2 - No	*(TETTNFAF)* 1st *(xxxx)* pg/mL	*(TET2TNFT)* ☐ 1 - Yes ☐ 2 - No	*(TETTNFAS)* 2nd *(xxxx)* pg/mL	*(TETTNFDT)* *(mm/dd /yyyy)*
30. Control IL-2:	*(CTRIL2TH)* ☐ 1 - Yes ☐ 2 - No	*(CTRLIL2F)* 1st *(xxxx)* pg/mL	*(CTR2IL2T)* ☐ 1 - Yes ☐ 2 - No	*(CTRLIL2S)* 2nd *(xxxx)* pg/mL	*(CTRIL2DT)* *(mm/dd /yyyy)*
31. Control IL-4:	*(CTRIL4TH)* ☐ 1 - Yes ☐ 2 - No	*(CTRLIL4F)* 1st *(xxxx)* pg/mL	*(CTR2IL4T)* ☐ 1 - Yes ☐ 2 - No	*(CTRLIL4S)* 2nd *(xxxx)* pg/mL	*(CTRIL4DT)* *(mm/dd /yyyy)*
32. Control IL-10:	*(CTRI10TH)* ☐ 1 - Yes ☐ 2 - No	*(CTRIL10F)* 1st *(xxxx)* pg/mL	*(CTR2I10T)* ☐ 1 - Yes ☐ 2 - No	*(CTRIL10S)* 2nd *(xxxx)* pg/mL	*(CTRI10DT)* *(mm/dd /yyyy)*
33. Control IFNg:	*(CTRIFNTH)* ☐ 1 - Yes ☐ 2 - No	*(CTRLIFNF)* 1st *(xxxx)* pg/mL	*(CTR2IFNT)* ☐ 1 - Yes ☐ 2 - No	*(CTRLIFNS)* 2nd *(xxxx)* pg/mL	*(CTRIFNDT)* *(mm/dd /yyyy)*

34. Control TNFa:	*(CTRTNFTH)* ☐ 1 - Yes ☐ 2 - No	*(CTRLTNFF)* 1st _____ *(xxxx)* pg/mL	*(CTR2TNFT)* ☐ 1 - Yes ☐ 2 - No	*(CTRLTNFS)* 2nd _____ *(xxxx)* pg/mL	*(CTRTNFDT)* _____ *(mm/dd /yyyy)*

35. Were the tetanus results abnormal for the 1 year visit?*(IREG1YR)* ☐ 1 - Yes ☐ 2 - No

If yes, enter the 15 month tetanus T cell blastogenesis:

	Is the first value below the threshold of detection?	Value	Is the second value below the threshold of detection?	Value	Date Test Performed
Proliferation					
36. Tetanus-specific profliferation:	*(TETTH15M)* ☐ 1 - Yes ☐ 2 - No	*(TETPR15M)* 1st _____ *(xxxxxx)* CPM	*(TH2PR15M)* ☐ 1 - Yes ☐ 2 - No	*(TE2PR15M)* 2nd _____ *(xxxxxx)* PCM	*(TET15MDT)* _____ *(mm/dd /yyyy)*
37. Control:	*(CTRTH15M)* ☐ 1 - Yes ☐ 2 - No	*(CTRPR15M)* 1st _____ *(xxxxxx)* CPM	*(CT2TH15M)* ☐ 1 - Yes ☐ 2 - No	*(CT2PR15M)* 2nd _____ *(xxxxxx)* PCM	*(CT15MDT)* _____ *(mm/dd /yyyy)*
Cytokine Secretion					
38. Tetanus-specific IL-2:	*(THIL215M)* ☐ 1 - Yes ☐ 2 - No	*(TETIL2FF)* 1st _____ *(xxxx)* pg/mL	*(TH2IL2M)* ☐ 1 - Yes ☐ 2 - No	*(TETIL2FS)* 2nd _____ *(xxxx)* pg/mL	*(TFUIL2DT)* _____ *(mm/dd /yyyy)*
39. Tetanus-specific IL-4:	*(THIL415M)* ☐ 1 - Yes ☐ 2 - No	*(TETIL4FF)* 1st _____ *(xxxx)* pg/mL	*(TH2IL4M)* ☐ 1 - Yes ☐ 2 - No	*(TETIL4FS)* 2nd _____ *(xxxx)* pg/mL	*(TFUIL4DT)* _____ *(mm/dd /yyyy)*
40. Tetanus-specific IL-10:	*(THI1015M)* ☐ 1 - Yes ☐ 2 - No	*(TEIL10FF)* 1st _____ *(xxxx)* pg/mL	*(TH21L10M)* ☐ 1 - Yes ☐ 2 - No	*(TEIL10FS)* 2nd _____ *(xxxx)* pg/mL	*(TFUI10DT)* _____ *(mm/dd /yyyy)*
41. Tetanus-specific IFNg:	*(THIFN15M)* ☐ 1 - Yes ☐ 2 - No	*(TEIFNGFF)* 1st _____ *(xxxx)* pg/mL	*(TH2IFNM)* ☐ 1 - Yes ☐ 2 - No	*(TEIFNGFS)* 2nd _____ *(xxxx)* pg/mL	*(TFUIFNDT)* _____ *(mm/dd /yyyy)*
42. Tetanus-specific TNFa:	*(THTNF15M)* ☐ 1 - Yes ☐ 2 - No	*(TETNFAFF)* 1st _____ *(xxxx)* pg/mL	*(TH2TNFM)* ☐ 1 - Yes ☐ 2 - No	*(TETNFAFS)* 2nd _____ *(xxxx)* pg/mL	*(TFUTNFDT)* _____ *(mm/dd /yyyy)*
43. Control IL-2:	*(CT15MI2T)* ☐ 1 - Yes ☐ 2 - No	*(CT15MI2F)* 1st _____ *(xxxx)* pg/mL	*(CT15M2ST)* ☐ 1 - Yes ☐ 2 - No	*(CT15MI2S)* 2nd _____ *(xxxx)* pg/mL	*(C15MI2DT)* _____ *(mm/dd /yyyy)*
44. Control IL-4:	*(CT15MI4T)* ☐ 1 - Yes ☐ 2 - No	*(CT15MI4F)* 1st _____ *(xxxx)* pg/mL	*(CT15M4ST)* ☐ 1 - Yes ☐ 2 - No	*(CT15MI4S)* 2nd _____ *(xxxx)* pg/mL	*(C15MI4DT)* _____ *(mm/dd /yyyy)*
45. Control IL-10:	*(CT15M10T)* ☐ 1 - Yes ☐ 2 - No	*(CT15M10F)* 1st _____ *(xxxx)* pg/mL	*(C15M10ST)* ☐ 1 - Yes ☐ 2 - No	*(CT15M10S)* 2nd _____ *(xxxx)* pg/mL	*(C15M10DT)* _____ *(mm/dd /yyyy)*
46. Control IFNg:	*(CT15MIGT)* ☐ 1 - Yes ☐ 2 - No	*(CT15MIGF)* 1st _____ *(xxxx)* pg/mL	*(C15MIGST)* ☐ 1 - Yes ☐ 2 - No	*(CT15MIGS)* 2nd _____ *(xxxx)* pg/mL	*(C15MIGDT)* _____ *(mm/dd /yyyy)*
47. Control TNFa:	*(CT15MTAT)* ☐ 1 - Yes ☐ 2 - No	*(CT15MTAF)* 1st _____ *(xxxx)* pg/mL	*(C15MTAST)* ☐ 1 - Yes ☐ 2 - No	*(CT15MTAS)* 2nd _____ *(xxxx)* pg/mL	*(C15MTADT)* _____ *(mm/dd /yyyy)*

Comments:*(SRFCMMTS)*

Blood and Marrow Transplant Clinical Trials Network

Toxicity Form - 0501 (TX8)

Web Version: 1.0; 2.00; 04-20-09

Segment *(PROTSEG)*:
Visit Number *(VISNO)*:

1. Record date of evaluation:*(TX8EVLDT)* _____ *(mm/dd/yyyy)*

Record the highest grade of toxicity diagnosed since the previous evaluation. If this is the first evaluation, record the highest toxicity diagnosed since Day 0. The toxicity grades are based on the NCI CTCAE Version 3.0.

GI Toxicity

2. Mucositis/stomatitis (clinical exam):*(TX8MCSTS)*

0 - Grades 0-2
3 - Confluent Ulcerations or Pseudomembranes; Bleeding with Minor Trauma
4 - Tissue Necrosis; Significant Spontaneous Bleeding; LT Consequences
5 - Death

Mouth pain or esophageal pain requiring IV hydration/narcotics.

Renal Toxicity

3. Did the patient experience renal failure severe enough to warrant dialysis?*(TX8RENAL)* ☐ 1 - Yes ☐ 2 - No

4. Did the patient receive dialysis?*(TX8DIALS)* ☐ 1 - Yes ☐ 2 - No

5. Hemorrhagic cystitis:*(TX8CYSTI)*

0 - Grades 0-2
3 - Transfusion; IV Pain Medications; Bladder Irrigation Indicated
4 - Catastrophic Bleeding; Major Non-Elective Intervention Indicated
5 - Death

Hemorrhagic Toxicity

6. Hemorrhage:*(TX8HEMRG)*

0 - Grades 0-3
4 - Catastrophic Bleeding; Requiring Major Non-Elective Intervention
5 - Death

Cardiovascular Toxicity

7. Hypotension:*(TX8HYPOT)*

0 - Grades 0-2
3 - Sustained (> or = 24 Hours) Therapy, Resolves Without Persisting Physiologic Consequences
4 - Shock (e.g., Acidemia; Impairment of Vital Organ Function)
5 - Death

8. Hypertension:*(TX8HYPER)*

0 - Grades 0-2
3 - Requiring More than One Drug or More Intensive Therapy than Previously
4 - Life-Threatening Consequences (e.g., Hypertensive Crisis)
5 - Death

9. Cardiac arrhythmia:*(TX8CRDAR)*

0 - Grades 0-2
3 - Incompletely Controlled Medically, or Controlled with Device (e.g., Pacemaker)
4 - Life-Threatening; Disabling (e.g., Arrhythmia Associated with CHF, Syncope, Shock)
5 - Death

10. Left ventricular systolic dysfunction:*(TX8LVENT)*

0 - Grades 0-2
3 - Symptomatic CHF Responsive to Intervention
4 - Refractory CHF or Poorly Controlled; Intervention with Ventricular Assist Device
5 - Death

11. Pericardial Effusion:*(TX8PREFF)*

0 - Grades 0-2
3 - Effusion with Physiologic Consequences
4 - Life-threatening Consequences, Emergency Intervention
5 - Death

12. Restrictive Cardiomyopathy:*(TX8RSTCA)*

0 - Normal
1 - Asymptomatic, No Therapy
2 - Asymptomatic, Therapy Indicated
3 - Symptomatic CHF, Intervention Responsive
4 - Refractory CHF, Poorly Controlled
*Additional Options Listed Below

Neurologic Toxicity

13. Somnolence:*(TX8SMNLN)*

0 - Grades 0-2
3 - Obtundation or Stupor; Difficult to Arouse; Interfering with ADL
4 - Coma
5 - Death

14. Did the patient experience any seizures during this assessment period?*(TX8SEIZR)* ☐ 1 - Yes ☐ 2 - No

15. Record seizure toxicity grade:*(TX8SZGRD)*

2 - One Brief Generalized Seizure; Seizure(s) Well Controlled by Anticonvulsants
3 - Seizures in Which Consciousness is Altered; Poorly Controlled Seizure Disorder
4 - Seizures of Any Kind Which are Prolonged, Repetitive or Difficult to Control
5 - Death

Coagulation Toxicity

16. HUS/TTP/thrombotic microangiopathy:*(TX8DIC)*

0 - Grades 0-3
4 - Laboratory Findings, Life-Threatening or Disabling Consequences
5 - Death

Vascular Toxicity

17. Vascular leak syndrome:*(TX8VASLK)*

0 - Grades 0-3
4 - Life-Threatening; Pressor Support or Ventilatory Support Indicated
5 - Death

Pulmonary Toxicity

18. Hypoxia (for more than 24 hours):*(TX8HYPXI)*

0 - Grades 0-2
3 - Decreased Oxygen Saturation at Rest; Continuous Oxygen Indicated
4 - Life-Threatening; Intubation or Ventilation Indicated
5 - Death

19. Dyspnea:*(TX8DYSPN)*

0 - Grades 0-2
3 - Dyspnea with Activities of Daily Living
4 - Dyspnea at Rest; Intubation or Ventilator Indicated
5 - Death

20. During this assessment period, was an FEV1 performed? *(TX8FEVDN)* ☐ 1 - Yes ☐ 2 - No

21. Record FEV1 value obtained:*(TX8FEVVL)* _____ *(xxx)* % of predicted value

22. During this assessment period, was an FVC performed? *(TX8FVCDN)* ☐ 1 - Yes ☐ 2 - No

23. Record FVC value obtained:*(TX8FVCVL)* _____ *(xxx)* % of predicted value

Hepatic Toxicity

24. ALT:*(TX8ALT)*

0 - Grades 0-2
3 - > 5.0 - 20.0 x ULN
4 - > 20.0 x ULN

25. Alkaline Phosphatase:*(TX8ALKPH)*

0 - Grades 0-2
3 - >5.0-20.0 x ULN
4 - >20.0 ULN

26. Did the patient develop abnormal liver function during this assessment period?*(TX8ABNLF)* ☐ 1 - Yes ☐ 2 - No

Did the patient develop any of the following clinical signs/symptoms of abnormal liver function during this assessment period?

27. Jaundice:*(TX8JANDC)* ☐ 1 - Yes ☐ 2 - No

28. Hepatomegaly:*(TX8HPTMG)* ☐ 1 - Yes ☐ 2 - No

29. Right upper quadrant pain:*(TX8QUADP)* ☐ 1 - Yes ☐ 2 - No

30. Weight gain (>5%) from baseline:*(TX8WGHTG)* ☐ 1 - Yes ☐ 2 - No

31. Other clinical signs/symptoms:*(TX8OTHAB)* ☐ 1 - Yes ☐ 2 - No

Specify other clinical signs/symptoms:*(TX8SPEC1)*

Indicate the etiology of the abnormal liver function:

	Etiology	Biopsy Results	Doppler Ultrasound Results
32. VOD:	*(TX8VODET)* 1 - Yes 2 - No	*(TX8VODBI)* 1 - Positive 2 - Negative 3 - Equivocal 4 - Not Done	*(TX8VODDP)* 1 - Confirmed 2 - Not Confirmed 3 - Not Done
33. GVHD:	*(TX8GVHET)* 1 - Yes 2 - No	*(TX8GVHBI)* 1 - Positive 2 - Negative 3 - Equivocal 4 - Not Done	*(TX8GVHDP)* 1 - Confirmed 2 - Not Confirmed 3 - Not Done
34. Infection:	*(TX8INFET)* 1 - Yes 2 - No	*(TX8INFBI)* 1 - Positive 2 - Negative 3 - Equivocal 4 - Not Done	*(TX8INFDP)* 1 - Confirmed 2 - Not Confirmed 3 - Not Done
35. Other:	*(TX8OTHET)* 1 - Yes 2 - No	*(TX8OTHBI)* 1 - Positive 2 - Negative 3 - Equivocal 4 - Not Done	*(TX8OTHDP)* 1 - Confirmed 2 - Not Confirmed 3 - Not Done
36. Unknown:	*(TX8UNKET)* 1 - Yes 2 - No	*(TX8UNKBI)* 1 - Positive 2 - Negative 3 - Equivocal 4 - Not Done	*(TX8UNKDP)* 1 - Confirmed 2 - Not Confirmed 3 - Not Done

Specify other etiology:*(TX8SPEC2)*

Comments:*(TX8COMM)*

Additional Selection Options for TX8

Restrictive Cardiomyopathy:
5 - Death